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ABSTRACT
Cancer has become number one cause of death. Conventional treatment includes
surgery, chemotherapy, radiation therapy, or combination. The combinatorial therapy
in one system is highly efficient and economical. Herein, two drug delivery systems
with chemo and photothermal therapy are developed in order to enhance the
therapeutic efficacy in A549 human lung cancer cells. The first one is hollow copper
sulfide nanoparticle carrying doxorubicin (PEG-HCuSNPs-DOX). The second one is
mesoporous silica coated CuS nanoparticles (CuS NPs) loaded with doxorubicin
(DOX) (PEG-CuS@MSNs-DOX).
Both nano-drug delivery systems are pH sensitive, laser responsive, and
photothermal convertible. CuS NPs are the photothermal sensitizers in both drug
delivery systems. However the drug loading efficiency is much higher in the
PEG-CuS@MSNs-DOX, whereas its drug release rate is much slower. In addition, the
anti-cancer

efficacy

of

PEG-HCuSNPs-DOX

is

higher

than

that

of

PEG-CuS@MSNs-DOX.
Five chapters are prepared in this thesis. Each chapter includes an independent
manuscript and separate abstract. Chapter 2 serves as preparation experiment for
chapter 3. Chapter 4 is a review that expands the application of CuS NPs to
transdermal delivery. Chapter 5 is a mini review on the in vivo application of CuS NPs
1. Cancer Photothermal Chemo Therapy Using Hollow Copper Sulfide
Doxorubicin	
  Nanoparticles

The design and synthesis of the multifunctional nanoparticles responsive to
external stimuli provides potential applications in biomedical fields such as controlled
drug delivery. Here, near infrared (NIR) laser-controlled fast and effective tumor cell
killing is achieved based on the pH sensitive and NIR light responsive hollow copper
sulfide nanoparticles chelated with doxorubicin molecules (HCuSNPs-DOX). Laser
exposure at 900 nm and acidic environment facilitate the release of DOX from
HCuSNPs-DOX. Spontaneously, the released DOX forms DOX/Cu2+ complex and
generates cell-killing reactive oxygen species. Laser exposure to HCuSNPs-DOX also
disrupts the integrity of the cell membrane instantly. The IC50 of HCuSNPs-DOX with
and without laser treatment was 4.0 and 7.6 µg/mL CuS, respectively. The approach
developed here offers compelling chances for quick-responsive anticancer therapy.
2. Facile Direct Dry Grinding Synthesis of Monodisperse Lipophilic CuS
Nanoparticles
Copper sulfide with near-infrared light absorption property is recently attracting
broad interest as a photothermal carrier for smart cancer therapy. Lipophilic copper
sulfide nanoparticle is preferred for high performance biomedical applications due to
the high affinity with tissues. But it requires complex multi-step synthetic process
under severe condition. Here, synthesis of hydrophobic copper sulfide possessing
surface plasmon resonance was retained by direct dry grinding of copper(II)
acetylacetonate with sulfur under ambient environment. The formed CuS
nanoparticles were in uniform size of ~10 nm, and they were monodispersed in pure
chloroform. Each covellite CuS nanocrystal surface was modified with oleylamine
through hydrogen bonding between sulfur atoms and amine groups of oleylamine.

While those oleylamine capped CuS nanoparticles showed uniform morphological
features, they demonstrated near-infrared light absorption for photothermal
applications. The facile and mild synthetic methodology described here opened a
powerful pathway for the design and preparation of photothermal lipophilic copper
sulfide nanomaterials for smart cancer therapy.
3. Multifunctional Mesoporous Silica-Coated CuS Nanoparticles for Cancer
Therapy: Synthesis, Characterization and in vitro Evaluation
Chemo therapeutic drug-caused side effects are commonly seen in clinical practice
due to nonspecific toxicity and low therapeutic efficiency. Herein, we reported a
cancer chemo-photothermal multifunctional drug delivery system. Polyethylene glycol
decorated

mesoporous

silica

nanoparticles

entrapping

CuS

nanoparticles

(PEG-CuS@MSNs) were successfully synthesized and characterized for the drug
delivery application. Doxorubicin (DOX)-loaded PEG-CuS@MSNs showed laser
stimulated and pH-responsive properties. In vitro cell experiments demonstrated that
DOX-loaded PEG-CuS@MSNs combining laser exposure achieved the highest rate of
death of A549 cells, in comparison to that of PEG-CuS@MSNs-DOX chemotherapy
alone. These findings provided a promising drug delivery system for cancer
combinatorial therapy, which could significantly reduce drug dose and improve patient
compliance.
4. Laser ablation-enhanced transdermal drug delivery
Transdermal delivery offers an excellent route for drug and vaccine administration.
Nonetheless, it presents a critical challenge due to the skin’s lipid-rich outer stratum

corneum layer. Laser ablation perforates epidermis through selective photothermolysis,
making skin more permeable to hydrophilic and macromolecular drugs such as
peptides, proteins, and genes. This review summarizes recent applications to laser
ablation-enhanced transdermal delivery. Needle- and pain-free transcutaneous drug
delivery via laser ablation provides an alternative approach to achieve local or
systemic therapeutics.
5. Cancer Photothermal Therapy and CuS Nanoparticles
This manuscript is being prepared according to the format of Lasers in Medical
Science as a review article.
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PREFACE
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the Format of Theses and Dissertations” standards for Manuscript format. This
dissertation is composed of four manuscripts that have been combined to satisfy the
requirements of the department of Biomedical and Pharmaceutical Sciences, College
of Pharmacy, University of Rhode Island.
Manuscript 1: Cancer Photothermal Chemo Therapy Using Hollow Copper
Sulfide Doxorubicin Nanoparticles
This manuscript is being prepared for submission to ACS nano.
Manuscript 2: Facile Direct Dry Grinding Synthesis of Monodisperse Lipophilic
CuS Nanoparticles
This manuscript is being prepared for submission to Materials Chemistry and
Physics.
Manuscript 3: Multifunctional Mesoporous Silica-Coated CuS Nanoparticles for
Cancer Therapy: Synthesis, Characterization and in vitro Evaluation
This manuscript is being prepared for submission to Journal of American Chemical
Society.
Manuscript 4: Yajuan Li, Liangran Guo, Wei Lu. Laser ablation-enhanced
transdermal drug delivery. Photonics and Lasers in Medicine. 2012, 2(4): 315–
322 (review)
This manuscript has been published as a review paper.
Manuscript 5: Cancer Photothermal Therapy and CuS Nanoparticles
This manuscript is being prepared for submission to Lasers in Medical Science.
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ABSTRACT: The design and synthesis of the multifunctional nanoparticles
responsive to external stimuli provides potential applications in biomedical fields such
as controlled drug delivery. Here, near infrared (NIR) laser-controlled fast and
effective tumor cell killing is achieved through the pH sensitive and NIR light
responsive hollow copper sulfide nanoparticles chelated with doxorubicin molecules
(PEG-HCuSNPs-DOX). Laser exposure at 900 nm and acidic environment facilitate
the release of DOX from PEG-HCuSNPs-DOX. Spontaneously, the released DOX
forms DOX/Cu2+ complex and generates cell-killing reactive oxygen species. Laser
exposure to PEG-HCuSNPs-DOX also disrupts the integrity of the cell membrane
instantaneously. The IC50 of PEG-HCuSNPs-DOX with and without laser treatment
was 4.0 and 7.6 µg/mL CuS, respectively. The approach developed here offers
compelling chances for controlled anticancer therapy.
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INTRODUCTION
Cancer has nowadays become one of the most deadly diseases in the world. As
reported in 2013, the 5-year global cancer prevalence is estimated to be 28.8 million in
a population of 49.2 million in 2008.1 Doxorubicin (DOX), as an effective tumor
chemotherapeutic drug, causes life-threatening dosage-dependent cardiac toxicity.2
Efforts in drug delivery have been made to enhance efficacy, reduce dosage, and
minimize side effects. The marketed DOX liposome injection Doxil®3 and various
multifunctional nanoparticles with assorted composites were developed as reviewed
by Prados4 and Hanušová.5
Copper sulfide nanoparticles are a new class of photothermal sensitizer providing
an affordable counterpart for gold nanoparticles. The light absorption of the former is
affected by the surrounding environment.6, 7 Originating from the d–d* transition of
Cu2+ ions in copper sulfide, such nanoparticle exhibits stable light absorption towards
near-infrared (NIR) light irradiation (650–900 nm),8 which can penetrate through
normal tissues with minimal thermal injury.9 Instantaneously upon NIR light
absorption, copper sulfide nanoparticles generated heat and photothermally ablated
tumor in vivo after intratumor10, 11 or intravenous injection.12 In our previous work,
hollow copper sulfide nanoparticles (HCuSNPs) were applied for photothermal
ablation-enhanced transdermal drug delivery.13 Once the HCuSNPs enriched on skin
surface was irradiated by nanosecond-pulsed NIR laser, high heat energy was
generated within very short time, which disrupted stratum corneum of the local skin
and facilitated permeation of human growth hormone. Recently, copper sulfide
nanoparticles were coated with DOX conjugated gelatin, achieving enzyme-responsive
3

drug release simultaneous photoacoustic imaging and photothermal therapy upon NIR
laser.14 Unfortunately, the resultant nanocomposites required relatively long time and
high power of NIR laser irradiation (> 5 min, 6 W/cm2) to achieve desired therapeutic
efficacy, which set barrier for practical applications in controlled cancer therapy.14
In this work, nanosecond-pulsed NIR laser controlled anticancer therapy is
achieved by PEG-HCuSNPs loaded with DOX. The shell of PEG-HCuSNP consists of
many 8-nm large polyethylene glycol (PEG) modified copper sulfide nanocrystals.
DOX molecules are loaded on the PEG-HCuSNPs through chelation. The pH-sensitive
nanocomposites tend to release a proportion of DOX after reaching the acidic tumor
site or lysosomes in the cells. NIR laser irradiation of the PEG-HCuSNPs-DOX
produces instantaneous heat and allows most of the DOX molecules to be released into
surrounding environment. The chemotherapy drug molecules further interact with
Cu2+ ions and generate reactive oxygen species (ROS), resulting in fast and highly
efficient pH-sensitive, chemo and photothermal cell killing effect. The current work
provides a facile and effective way for smart controlled antitumor therapy.
RESULTS AND DISCUSSION
The preparation of PEG-HCuSNPs-DOX was carried out as illustrated in Scheme
1.
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Scheme

1.

Schematic

illustration

of

the

preparation

procedure

of

the

PEG-HCuSNPs-DOX and NIR laser controlled drug release process.
The transmission electron microscopy (TEM) image of the as-prepared HCuSNPs
demonstrated hollow structures with the average diameter of 75 ± 11 nm (Figure 1a).
The shells were ~20-nm thick, and consisted of 8-12-nm large nanoparticles. After
surface modification with thiolated PEG, a thin layer (thickness ~4 nm) was clearly
observed on the particle surfaces, while the initial structures of HCuSNPs did not
change (Figure 1b). Loading of DOX did not significantly change the size and
morphology of the nanoparticles (Figure 1c). Dynamic light scattering (DLS) analysis
revealed that the hydrodynamic particle size of the PEG-HCuSNPs-DOX was 80 ± 10
nm, which agreed well with the TEM observations. As shown in the UV–Vis spectrum
(Figure 1d), PEG-HCuSNPs exhibited strong absorbance peak centered at ~1050 nm,
which was ascribed to the d–d* transition of copper sulfide.20 Similar absorbance was
found in the UV–Vis spectrum of PEG-HCuSNPs-DOX, but with a minor red shift of
5 nm due to the DOX chelation on HCuSNPs.15 When compared with the green
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aqueous

dispersion

of

PEG-HCuSNPs,

the

aqueous

dispersion

of

PEG-HCuSNPs-DOX was more brownish (Figure 1e). The drug loading increased
with the increase of time (Figure 1f). The PEG-HCuSNPs and PEG-HCuSNPs-DOX
remained stable in DI water at room temperature for at least 3 months. The DOX
loading efficiency of the PEG-HCuSNPs-DOX was optimized ~6.0 wt.%.
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Figure 1. TEM images of HCuSNPs (a), PEG-HCuSNPs (b), PEG-HCuSNPs-DOX
(c), Bars, 50 nm. UV–vis spectra (d), the inset is the enlarged UV–vis spectra.
Photograph

of

the

dispersions

(e)

containing

PEG-HCuSNPs

(left)

and

PEG-HCuSNPs-DOX (right). Loading efficiency change over 5 days (f). Samples
were taken at time point 0, 0.42 , 1, 2, 3 and 5 day. Data were expressed as Mean ± SD.
n=3.
The drug release profiles of HCuSNPs-DOX were studied in the media with
respective pH of 7.4, 6.0 and 5.0 over a 4-h period. Without laser irradiation, the
cumulative release of DOX was 16.6%, 23.0% and 33.9%, respectively (Figure 2).
DOX release from PEG-HCuSNPs-DOX was pH dependent. On the other hand, NIR
laser irradiation accelerated DOX release in various pH conditions. While the DOX
released in 1 h was 3.8 ± 2.2% (pH 7.0), 12.6 ± 0.9% (pH 6.0), and 25.0 ± 2.7% (pH
5.0), the released amount increased to 27.9 ± 0.9%, 37.8 ± 2.0%, and 47.7 ± 3.7%
after the first laser irradiation (2.0 W/cm2, 15 s, 900nm). The drug release slowed
down when the laser was switched off. The laser-triggered release was well responsive
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to the repeated laser irradiation. By the end of 4 h with 3 times of laser exposure, the
cumulative release of DOX reached 48.1%, 58.7% and 75.6% at pH 7.4, 6.0 and 5.0,
respectively. Significantly, in the pH 5.0 medium, the cumulative release of DOX with
NIR laser treatment was 2.2 folds higher compared with that without laser irradiation.
The dual-module release profile of PEG-HCuSNPs-DOX presented a spatiotemporal
controlled release manner through which the drug can be specifically released at the
tumor site either applying NIR laser or under the acidic environment of the tumor.16

Figure 2. DOX cumulative release from PEG-HCuSNPs-DOX under different pH
buffers containing 10% BSA. The laser irradiation was administrated at time point 1, 2
and 3 h. (2 W/cm2, 15 s, red lines). Data were expressed as Mean ± SD. n=3.
As reported, DOX formed water soluble complexes with Cu2+ below pH 8.
Specifically, within pH range of 4.2 to 5.8, the drug and Cu2+ formed incomplete 2:1
DOX/Cu2+ complex; at pH 5.8, 2:1 ratio complex formed exclusively regardless of
8

excessive copper; above 5.8, both DOX/Cu2+ complexes with ratio of 1:1 and 2:1
existed; and at pH 7.3, only 1:1 complex was obtained.17 To test whether the
laser-treated PEG-HCuSNPs-DOX released free drug only or both free drug and
copper ion, or even further to form DOX/Cu2+ complex, we used the UV–vis, circular
dichroism (CD), and fluorescence spectra to characterize free DOX, DOX/Cu2+
complex and the supernatant of PEG-HCuSNPs-DOX with or without NIR laser
irradiation at pH 5 and 6. UV and CD spectra of samples at pH 7.4 were not able to be
analysed due to the limitation of sampling quantity and the instrument sensitivity,
however, inductively coupled plasma mass spectrometry (ICP-MS, data not shown)
and fluorescence data clearly indicating the existence of copper and doxorubicin. At
pH 5, the band intensity of DOX near 478 and 498 nm decrease upon the partial
formation of DOX/Cu2+ 2:1 complex. In addition, the absorbance peak near 535 nm
increased (Figure 3a). The released samples with or without laser treatment all showed
similar absorbance curves to the complex rather than free DOX, indicating formation
of the DOX/Cu2+ complex. When pH increased to 6, both 2:1 and 1:1 complex exist.
As shown in Figure 3a, the absorbance of the DOX/Cu2+ complex at 480 nm continued
to decrease and the broad band was centered at 506 nm. The band at 550 nm increased
significantly. The released samples showed similar changes.
In comparison with free DOX, the CD spectrum of DOX/Cu2+ at pH 5 and 6
showed negative and positive bands at 490 and 550 nm respectively, which were
typical of DOX/Cu 2:1 complexes (Figure 3b). The same trend was shown in the
supernatant from laser treated PEG-HCuSNPs-DOX at pH 5 and 6. Combining the
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UV results, it could be concluded that the DOX/Cu2+ 2:1 complex forms after laser
treatment at pH 5 and 6.
Fluorescent spectra of the DOX and Cu2+ mixture demonstrated the reduced
fluorescent intensity at both pH 5 and 6, indicating the formation of DOX/Cu2+
complex, the fluorescence of which was quenched (Figure 3c). It should be noticed
that as pH increased from 5 to 6 and 7.4, the intensity decreased, revealing that more
free DOX were chelated by Cu2+. Addition of excess ethylenediaminetetraacetic acid
(EDTA) with 1 h incubation at 60 ºC recovered the fluorescence intensity since EDTA
competed for the ligation of Cu2+.18 The same trend was shown in the supernatant
from laser treated PEG-HCuSNPs-DOX at pH 5, 6 and 7.4. In addition, the released
amount of DOX was pH-dependent. At pH 5, the laser treated PEG-HCuSNPs-DOX
sample showed the highest absorbance of DOX among the different buffer solution
groups.

10
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Figure 3. UV-vis (a) and CD (b) spectra of 100 µM DOX, 100 µM DOX/Cu2+, 100
µM DOX released from PEG-HCuSNPs-DOX and 100 µM DOX released from
HCuSNPs-DOX with laser treatment in the medium of pH 5, 6 acetic buffer solution.
Fluorescence (c) spectra of 100 µM DOX, 100 µM DOX/Cu2+, 100 µM DOX/Cu2+
+EDTA and DOX released from PEG-HCuSNPs-DOX containing 100 µM DOX in
the medium of pH 5, 6 acetic buffer solution and pH 7.4 phosphate buffer solution
respectively. Released samples were incubated with excessive EDTA for 1 h at 60 ºC
to recover the fluorescence of DOX.
To ensure the successful uptake of PEG-HCuSNPs-DOX into cells, uptake and
elimination studies were performed. The result showed that the intracellular amount of
DOX reached plateau at 2 h following incubation with either free DOX or
PEG-HCuSNPs-DOX (Figure 4). The uptake of DOX in PEG-HCuSNPs-DOX was
1.23 fold as high as that of free DOX (p<0.05). There was no significant difference in
elimination profile between PEG-HCuSNPs-DOX and free DOX following 4-h
uptake.
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Figure 4. Intercellular uptake and eliminate of DOX or PEG-HCuSNPs-DOX after the
4-h uptake. Mean ± SD, n= 3. (* p < 0.05)
To investigate the mechanism of drug release in vitro, cell lysosome was stained with
Lysotracker Blue to track the intracellular distribution of the drug. As shown in Figure
5a, most of the fluorescence of DOX colocalized with that of Lysotracker, and
achieved high intensity adjacent to the nuclei, suggesting intracellular uptake of DOX
through the process of endocytosis of the PEG-HCuSNPs-DOX. Upon laser exposure,
the fluorescence of DOX spread throughout the cells except nuclei, indicating
laser-induced endolysosomal escape of the nanoparticles and drug release into
cytoplasm (Figure 5b). This was attributed to photothermally induced disruption of
endolysosomal membranes mediated by HCuSNPs.19
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Figure 5. Fluorescent microscopy images of A549 cells incubated for 4 h with
PEG-HCuSNPs-DOX (a) and PEG-HCuSNPs-DOX plus laser ( 2.0 W/cm2, 15 s) (b)
at the end of incubation. Lysosome fluorescence (pseudo-green); DOX fluorescence
(red); overlap (yellow). Scale bar: 50 µm.
DOX induced the generation of reactive oxygen species (ROS), thus causing the
oxidation of lipid, protein, and DNA in cancer cells20–25. More interestingly, transition
metal ion has been indicated to be a critical cofactor facilitating this process.15 To
prove that DOX/Cu2+ complex released from PEG-HCuSNPs-DOX could assist ROS
generation and therefore induce therapeutic effects on cancer cells, ROS level was
tested via fluorescence imaging and quantification. As shown in the fluorescent
microscope images (Figure 6a), only weak signal of ROS species was detected from
free DOX, PEG-HCuSNPs or PEG-HCuSNPs with NIR laser exposure. However,
existence of ROS was clearly shown by the green fluorescence in the cases of
PEG-HCuSNPs-DOX and DOX/Cu2+ complex with NIR laser irradiation (Figure 6a).
The intensity of reactive oxygen species signal increased after NIR laser irradiation
(Figure 6b), because the HCuSNPs released Cu2+ ions
14

13

and facilitated DOX

molecules to chelate with Cu2+. As comparisons, the generation of reactive oxygen
species by hollow gold nanoparticles (HAuNPs) and DOX modified gold
nanoparticles (HAuNPs-DOX) was studied under the identical condition. However, no
such fluorescence was observed from either sample despite of the NIR laser irradiation
(Figure 6b). Therefore, the cancer killing effect of PEG-HCuSNPs-DOX could be
attributed to a combination of DOX release, photothermal effect, and copper induced
ROS generation following NIR laser irradiation. The One-way analysis of variance
(One-way ANOVA) results were shown in Table 1. and Table 2.
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Figure 6. (a) Fluorescence microscopy images of A549 cells incubated for 2 h with
DOX, DOX/Cu2+, PEG-HCuSNPs or PEG-HCuSNPs-DOX and then treated with the
NIR laser ( 2.0 W/cm2, 15 s). The cells were sustained with fluorogenic probe
2’,7’-dichlorodihydrofluorescin diacetate (DCFH-DA). Green fluorescence indicated
the existence of ROS. Scale bar: 50 µm. (b) Normalized ROS intensity before and
after treatments. (* P<0.05 when compared with free DOX. Mean ±SD, n=3).

Table 1. ANOVA Result
ROS Level
Sum of Squares
Between Groups
Within Groups
Total

df

Mean Square

16.696

9

1.855

2.824

30

.094

19.521

39

16

F
19.704

Sig.
.000

Table 2. Multiple Comparisons
Dependent Variable: ROS Level
Tukey HSD
(I) GROUP

(J) GROUP

Mean

Std.

Difference

Error

Sig.

Interval

(I-J)

Bound

Bound

.001

-1.811

-.330

-.3350

.2170

.863

-1.075

.405

*

.2170

.000

-1.913

-.432

-.2250

.2170

.987

-.965

.515

*

.2170

.000

-2.063

-.583

-.7375

.2170

.050

-1.478

.003

*

.2170

.000

-2.723

-1.242

HAuNP-DOX

-.0270

.2170

1.000

-.767

.713

HAuNP-DOX + Laser

-.0083

.2170

1.000

-.748

.732

*

.2170

.001

.330

1.811

.7355

.2170

.052

-.005

1.476

-.1020

.2170

1.000

-.842

.638

PEG-HCuSNPs-DOX
+ Laser
DOX + Laser
DOX/CU2+ + Laser
PEG-HCuSNPs +
Laser
PEG-HCuSNPS-DOX
+ Laser

DOX

-1.0705

-1.1725

-1.3233

-1.9825

1.0705

PEG-HCuSNPS
PEG-HCuSNPs-DOX
+ Laser
DOX + Laser

.8455

*

.2170

.016

.105

1.586

DOX/CU2+ + Laser

-.2528

.2170

.972

-.993

.487

.3330

.2170

.867

-.407

1.073

-.9120

*

.2170

.007

-1.652

-.172

1.0435

*

.2170

.001

.303

1.784

1.0622

*

.2170

.001

.322

1.802

.3350

.2170

.863

-.405

1.075

-.7355

.2170

.052

-1.476

.005

*

.2170

.017

-1.578

-.097

.1100

.2170

1.000

-.630

.850

*

.2170

.003

-1.728

-.248

PEG-HCuSNPs +
Laser
PEG-HCuSNPS-DOX
+ Laser
HAuNP-DOX
HAuNP-DOX + Laser
DOX
DOX/CU2+

PEG-HCuSNPS

Upper

.2170

PEG-HCuSNPS

DOX/CU2+

Lower

*

DOX/CU2+

DOX

95% Confidence

PEG-HCuSNPs-DOX
+ Laser

-.8375

DOX + Laser
DOX/CU2+ + Laser

-.9883
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PEG-HCuSNPs +

-.4025

.2170

.697

-1.143

.338

*

.2170

.000

-2.388

-.907

HAuNP-DOX

.3080

.2170

.911

-.432

1.048

HAuNP-DOX + Laser

.3267

.2170

.879

-.413

1.067

*

.2170

.000

.432

1.913

.1020

.2170

1.000

-.638

.842

.8375

*

.2170

.017

.097

1.578

DOX + Laser

.9475

*

.2170

.005

.207

1.688

DOX/CU2+ + Laser

-.1508

.2170

.999

-.891

.589

.4350

.2170

.602

-.305

1.175

-.8100

*

.2170

.023

-1.550

-.070

1.1455

*

.2170

.000

.405

1.886

1.1642

*

.2170

.000

.424

1.904

.2250

.2170

.987

-.515

.965

DOX/CU2+

-.8455

*

.2170

.016

-1.586

-.105

PEG-HCuSNPS

-.1100

.2170

1.000

-.850

.630

-.9475

*

.2170

.005

-1.688

-.207

-1.0983

*

.2170

.001

-1.838

-.358

-.5125

.2170

.382

-1.253

.228

*

.2170

.000

-2.498

-1.017

HAuNP-DOX

.1980

.2170

.995

-.542

.938

HAuNP-DOX + Laser

.2167

.2170

.990

-.523

.957

*

.2170

.000

.583

2.063

.2528

.2170

.972

-.487

.993

*

.2170

.003

.248

1.728

.1508

.2170

.999

-.589

.891

*

.2170

.001

.358

1.838

.5858

.2170

.219

-.154

1.326

-.6592

.2170

.113

-1.399

.081

*

.2170

.000

.556

2.036

Laser
PEG-HCuSNPS-DOX
+ Laser

DOX

-1.6475

1.1725

DOX/CU2+
PEG-HCuSNPS

PEG-HCuSNPs-DOX
+ Laser

PEG-HCuSNPs +
Laser
PEG-HCuSNPS-DOX
+ Laser
HAuNP-DOX
HAuNP-DOX + Laser
DOX

PEG-HCuSNPs-DOX
+ Laser
DOX + Laser

DOX/CU2+ + Laser
PEG-HCuSNPs +
Laser
PEG-HCuSNPS-DOX
+ Laser

DOX

-1.7575

1.3233

DOX/CU2+
PEG-HCuSNPS

.9883

PEG-HCuSNPs-DOX
+ Laser
DOX/CU2+ + Laser

DOX + Laser

1.0983

PEG-HCuSNPs +
Laser
PEG-HCuSNPS-DOX
+ Laser
HAuNP-DOX

1.2963
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*

.2170

.000

.575

2.055

.7375

.2170

.051

-.003

1.478

-.3330

.2170

.867

-1.073

.407

.4025

.2170

.697

-.338

1.143

-.4350

.2170

.602

-1.175

.305

.5125

.2170

.382

-.228

1.253

-.5858

.2170

.219

-1.326

.154

*

.2170

.000

-1.985

-.505

HAuNP-DOX

.7105

.2170

.068

-.030

1.451

HAuNP-DOX + Laser

.7292

.2170

.056

-.011

1.469

1.9825

*

.2170

.000

1.242

2.723

.9120

*

.2170

.007

.172

1.652

1.6475

*

.2170

.000

.907

2.388

.8100

*

.2170

.023

.070

1.550

1.7575

*

.2170

.000

1.017

2.498

.6592

.2170

.113

-.081

1.399

1.2450

*

.2170

.000

.505

1.985

1.9555

*

.2170

.000

1.215

2.696

1.9742

*

.2170

.000

1.234

2.714

.0270

.2170

1.000

-.713

.767

*

.2170

.001

-1.784

-.303

-.3080

.2170

.911

-1.048

.432

*

.2170

.000

-1.886

-.405

-.1980

.2170

.995

-.938

.542

*

.2170

.000

-2.036

-.556

-.7105

.2170

.068

-1.451

.030

*

.2170

.000

-2.696

-1.215

HAuNP-DOX + Laser

.0187

.2170

1.000

-.721

.759

DOX

.0083

.2170

1.000

-.732

.748

*

.2170

.001

-1.802

-.322

-.3267

.2170

.879

-1.067

.413

HAuNP-DOX + Laser

1.3150

DOX
DOX/CU2+
PEG-HCuSNPS
PEG-HCuSNPs-DOX
PEG-HCuSNPs +
Laser

+ Laser
DOX + Laser
DOX/CU2+ + Laser
PEG-HCuSNPS-DOX
+ Laser

DOX
DOX/CU2+
PEG-HCuSNPS
PEG-HCuSNPs-DOX
PEG-HCuSNPS-DOX
+ Laser

+ Laser
DOX + Laser

-1.2450

DOX/CU2+ + Laser
PEG-HCuSNPs +
Laser
HAuNP-DOX
HAuNP-DOX + Laser
DOX
DOX/CU2+
PEG-HCuSNPS
PEG-HCuSNPs-DOX
+ Laser

HAuNP-DOX

DOX + Laser
DOX/CU2+ + Laser
PEG-HCuSNPs +
Laser
PEG-HCuSNPS-DOX
+ Laser

HAuNP-DOX + Laser DOX/CU2+
PEG-HCuSNPS

-1.0435

-1.1455

-1.2963

-1.9555

-1.0622
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PEG-HCuSNPs-DOX
+ Laser
DOX + Laser
DOX/CU2+ + Laser
PEG-HCuSNPs +
Laser
PEG-HCuSNPS-DOX
+ Laser
HAuNP-DOX

*

.2170

.000

-1.904

-.424

-.2167

.2170

.990

-.957

.523

*

.2170

.000

-2.055

-.575

-.7292

.2170

.056

-1.469

.011

*

.2170

.000

-2.714

-1.234

-.0187

.2170

1.000

-.759

.721

-1.1642

-1.3150

-1.9742

*. The mean difference is significant at the 0.05 level.

The total effect of PEG-HCuSNPs-DOX on cell viability was evaluated using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. As shown
in Figure 7a, NIR laser exposed PEG-HCuSNPs-DOX exhibited the highest
anti-cancer effect within the concentration of 0.002–0.78 µg/mL DOX 24 h after
treatment. The IC50 of PEG-HCuSNPs-DOX combining NIR laser treatment was 0.11
µg/mL DOX. The IC50 of PEG-HCuSNPs-DOX without NIR laser treatment was 0.21
µg/mL DOX. Comparatively, the IC50 of PEG-HCuSNPs with and without laser and
was 0.24 and 2.07 µg/mL in DOX, respectively. The administration of NIR laser
drastically decreased the viability for cells treated with PEG-HCuSNPs and
PEG-HCuSNPs-DOX when compared with the non-laser groups at comparative
concentration. Besides, the IC50 of HAuNPs-DOX on A549 cells with laser (2.0
W/cm2, 15 s) dose was 2.2 µg/mL DOX, while the IC50 of PEG-HCuSNPs-DOX with
the same laser dose was 0.11 µg/mL DOX, significantly less than the former
treatment.
Further, we used propidium iodide ( PI ) staining to test whether the nanoparticles
could bring quick damage to cell membrane upon NIR laser administration because PI
20

is a fluorescence marker permeable to porous cell membrane and staining nuclei
selectively. For the PEG-HCuSNPs-DOX group, the ratio of the PI stained cells to the
total cells immediately after the NIR laser irradiation was much higher than that of
PBS control, PBS with laser treatment or even free DOX under identical experimental
condition (Figure 7b). In addition, the HAuNPs-DOX with laser treatment didn’t show
significant difference from the PBS control group. It should be noticed that the laser
induced cell death by PI staining at 4 h after laser treatment was less effective than
that from the cell viability assay at 24 h after treatment.

This result indicated that

laser-induced instantaneous ablation to the cell membrane was only one among
various modalities that PEG-HCuSNPs-DOX caused cancer cell death. Other
modalities also played important role in causing cell death progressively and
accumulatively, including the DOX or DOX/Cu2+ complex induced toxicity and ROS
species.
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Figure 7. (a) and (b) 24-h viability of A549 cells exposed to different concentration of
nanoparticles or DOX with or without NIR laser irradiation ( 2.0 W/cm2, 15 sec) by
MTT assay. Data are plotted as the percentage of viable cells compared to untreated
controls. Each value represents mean ± SD (n = 3). (c) Percentage of PI stained A549
cells exposed to different treatment of 0.5 µg/mL DOX equivalent after 4-h incubation
followed successively by NIR laser irradiation ( 2 W/cm2, 15 s). The control group
was treated with PBS. (*P< 0.05 as compared with control. Percentage = PI stained
cells/total cells counted × 100%, n=3 )
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SUMMARY AND CONCLUSIONS
In summary, NIR laser controlled anticancer nanocomposite was achieved by
modification of PEG-HCuSNPs with DOX through chelating interaction. The
nanocomposite was capable of pH-sensitive drug release, photothermal conversion,
and generating ROS in response to NIR laser irradiation. With the NIR laser
responsive multi-functions, highly controlled and effective cancer killing performance
was achieved. The current work sheds a considerable light on the smart antitumor
materials by NIR laser control for transdermal cancer therapy.
METHODS
Chemicals. Doxorubicin hydrochloride and Dulbecco's Modified Eagle Medium
(DMEM)

were

purchased

from

AK

scientific

and

Lonza,

respectively.

Lysotraker®Blue DND-22 and propidium iodide were supplied from Life
Technologies. A549 cell line was obtained from American Type Culture Collection
(ATCC). All the other chemicals were bought from Sigma-Aldrich without further
purification. The water was purified by using a Milli-Q Synthesis system (Millipore)
with the resistivity higher than 18.2 MΩ·cm.
Materials Preparations. HCuSNPs was synthesized according to the previous
reports.6,13 Briefly, 0.24 g poly(vinylpyrrolidone) and 25 mL sodium hydroxide
aqueous solution (pH 9.0) were successively added into 25 mL 0.05 mM copper
chloride aqueous solution, and the mixture was stirred vigorously at room temperature.
Subsequently, 2.0 mL 0.10 M hydrazine hydrate solution was added, and suspension
was formed after reaction for 5 min. Then, 0.266 mmol sodium sulfide was added to
the suspension and stirred at 60 °C for 1 h. The formed HCuSNPs was collected by
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centrifuging at 11,000 rpm for 10 min, washing three times with pure water and
suspending in 5 mL pure water.
To prepare PEG-HCuSNPs-DOX, 20 µL thiolated PEG was added to 5 mL
aqueous dispersion of 18 mg HCuSNPs and stirred overnight at 1000 rpm. The
resultant PEG-HCuSNPs was washed three times by centrifuging at 12 000 rpm for 10
min for three times. Then, 1 mL 1 mg/mL Doxorubicin hydrochloride aqueous
solution was mixed with the above dispersion containing PEG-HCuSNPs and stirred
at 1000 rpm for 24 h. After washing with water for three times, PEG-HCuSNPs-DOX
was obtained.
Characterizations. To prepare samples for transmission electron microscope
(TEM) observations, the corresponding materials were ultrasonicated in pure water
until homogeneous suspension was formed, and the resulting suspension was then
dropped onto a nickel micro grid, followed by drying in air. TEM observations were
respectively performed on a JEOL 2100EX microscope operating at an accelerating
voltage of 100 kV. DLS analysis was proceeded with the Malvern® nanoseries
Nano-ZS90 nanoparticle size analyzer. UV–visible–NIR absorbance spectra were
obtained with a Beckmann Coulter DU800 UV–visible–NIR spectrophotometer with a
quartz cuvette of 1.0 cm optical path length in the transmission mode employing pure
water as the reference standard. Circular Dichroism spectra were acquired by Jasco
J-810 Circular Dichroism spectropolarimeter (163~900 nm). Fluorescent spectra were
measured by SpectraMax Multi-Mode Microplate Readers.
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The DOX loading efficiency was calculated from the weight of DOX component
detached from the PEG-HCuSNPs-DOX. The washed PEG-HCuSNPs-DOX was
mixed with 0.5 mL of 10 mM EDTA and 5 µL of 2 M HCl and incubated at 60 °C for
1 h. Then, the dispersion was centrifuged at 12000 rpm for 10 minutes. The
supernatant was collected and analyzed by fluorescent spectroscopy to determine the
weight of DOX extracted. The DOX loading efficiency was calculated via the
following equation:

E DOX =

W DOX
W PEG − HCuSNPs

(1)

× 100%

where EDOX represents the DOX loading efficiency, WDOX stands for the weight of
DOX extracted from the nanoparticles, and the WPEG-HCuSNPs-DOX shows the weight of
PEG-HCuSNPs added.
Cell Culture. A549 cell line was cultured in DMEM media, supplemented with
10% fetal bovine serum (FBS), L-glucose, glutamine, 100 U/mL penicillin and 100
µg/mL streptomycin.
In Vitro Release. In vitro release of DOX from the as-prepared nanoparticles by
adding 10 mg PEG-HCuSNPs-DOX in a dialysis tube (1000 Da cut off;
Sigma-Aldrich), placing the tube in 100 mL of phosphate-buffered saline (PBS, pH
7.4, 10 mM) containing 10% BSA, and shaking constantly at 150 rpm at 37°C. The
NIR laser was administered as needed after taking out the sample from the dialysis
tube at 2.0 W/cm2 for 15 s at a time interval of 1 h. The in vitro DOX release was
continued for 4 h. The release medium was replaced with a fresh one at a determined
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interval to maintain sink conditions. The amount of released DOX was monitored by
fluorescent measurement. The fluorescent emission peak at λ = 590 nm under
excitation light (λ = 485 nm) of each solution was recorded to determine the released
DOX amount. As a comparison, in vitro release was proceeded identically without
NIR irradiation.All measurements were performed in triplicate.
MTT

Assay.

Cell

viability

was

measured

by

the

3-[4,5-dimethylthylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) method.
Briefly, A549 cells were seeded in 96-well plates at a density of 5 × 103 cells per well
and incubated for 24 h prior to use. The cells were respectively incubated with blank
PEG-HCuSNPs,

PEG-HCuSNPs-DOX,

and

free

DOX

at

equivalent

drug

concentrations ranging from 50 nM to 15 000 nM for 4 h. After replacing the culture
medium with FBS-free DMEM and irradiation with NIR laser at 2 W/cm2 for 15 s, the
FBS-free DMEM was substituted with DMEM containing 10% FBS and the cells
were further incubated for 24 h. Then, MTT tetrazolium salt (0.25 mg/ml) was added
to each well and incubated in CO2 incubator at 37°C for 4 h. Finally, 150 µL DMSO
was added to each well dissolve formazan crystals and the UV–vis absorbance peak at
570 nm was monitored by a plate reader. 26
ROS Assay A549 cell line was cultured in the coverglass chambers at a
concentration of 20,000 per well, and free DOX, DOX/Cu2+ complex (DOX:Cu2+ =
1:1), PEG-HCuSNPs, and PEG-HCuSNPs-DOX were respectively added to each well.
The final concentration of DOX was 0.5 µM, and the amount of PEG-HCuSNPs was
kept the same in the wells. After incubating for 4 h, the drug-containing medium was
replaced with new one and irradiated with NIR laser (900 nm, 2 W/cm2, 15 s) . Then,
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the medium was substituted with 1 mM DFCH-DA medium and incubated for 30 min.
After washing with PBS for 3 times, the wells were observe by using the fluorescent
microscope.
To determine the ROS level in A549 cells, A549 cell line was cultured in the
96-well plate at a concentration of 10,000 per well. Then, the cells were treated
identically by replacing the cell culture medium with DMEM, incubated for 3 h,
changing the culture medium with pre-warmed freshmedium, adding samples,
incubated for 4h, replacing medium with DMEM, exposed with corresponding light
irradiations, substituting the medium with 1 mM DFCH-DA medium, incubated for 30
min, washing with PBS for 3 times, adding 100 µL cell lycis buffer. Finally, the
treated specimens were subjected to fluorescent test (excitation λ = 480 nm, emission λ
= 530 nm) to measure the protein content. As a comparison, DMEM containing 5 mM
NAC was applied as the cell culture medium and tested through the same procedure.
PI exclusion assay. A549 cell viability was determined by staining the cells with
propidium iodide according to the manufacturer's instructions. In a typical procedure,
the A549 cells were seeded into 96-well culture plates at a concentration of 1.5 × 105
cells per well and incubated for 24 h to allow cell attachment. The cells were
respectively administered with free DOX, PEG-HCuSNPs-DOX, and PEG-HCuSNPs
at equivalent drug concentrations (5 µM) for 4 h. The washing procedure is the same
as MTT assay. After NIR laser irradiation, the cells were collected by trypsinization
using a 0.125% trypsin solution. The cells collected were washed twice with PBS (pH
= 7.4) and re-suspended in 100 µL PBS at a density of 1×105 cell mL–1. Subsequently,
5 µL of propidium iodide solution (100 µg mL–1) and 400 µL of PBS solution were
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successively added to the cells. The cells were further incubated for 5 min in darkness,
and the total number of the cells stained was counted with a cellometer (Nexcelom
vision).
Intracellular Uptake. For the PEG-HCuSNPs-DOX uptake study, 12-well
plates were seeded with A549 cells at 2 × 105 per well, and the cells were allowed to
attach for 24 h. The medium was replaced with 1 mL of medium containing
PEG-HCuSNPs-DOX or DOX solution (final Dox concentration 5 µM), and the
samples were incubated for a determined time period (0.5 h and 2 h). The cells were
washed three times with PBS buffer to remove the excess drug component, and then
the cells were lysed in 100 µL of cell lysis buffer for 10 min. 10 mL portion of the
resultant cell lystate was used to quantify the protein concentration through the BCA
protein assay. The remained cell lystate dispersion was mixed with 0.2 mL of acidified
methanol solution (0.1 M HCl in 90% methanol) and centrifuged at 16800 rpm for 10
min. The supernatant was extracted and subjected for fluorescent spectroscopy to
analyze DOX level. The fluorescent emission peak at λ = 591 nm was detected under
excitation λ = 485 nm. The data were normalized to per milligram cell protein.
Intracellular Elimination. For the PEG-HCuSNPs-DOX elimination study,
12-well plates were seeded with A549 cells at 2 ×105 per well, and the cells were
allowed to attach for 24 h. The medium was replaced with 1 mL medium containing
PEG-HCuSNPs-DOX or Dox solution (final DOX concentration 5 µM) and incubated
for 4 h. The cells were washed three times to remove the free DOX or
PEG-HCuSNPs-DOX with PBS buffer and continued to incubate with fresh medium.
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Intracellular DOX level was determined after being washed for 12 h, 24 h and 48 h via
the same method as described in the intracellular uptake assay section.
Lysotracking. The lysotracking study was carried out by using Lysotraker®Blue
DND-22. Generally, 8-well cover slide chambers were seeded with A549 cells at 2
×105 per well, and the cells were left for 24 h to achieve attachment. The cells were
incubated for 4 h with 0.5 µg/mL PEG-HCuSNPs-DOX or PEG-HCuSNPs-DOX plus
laser ( 2.0 W/cm2, 15 s) at the end of incubation. Then the initial medium was
removed from the chamber, and the pre-warmed probe-containing medium (37°C) was
added and incubated for 30 min. The cells were washed with phenol red-free DMEM
for 3 times, and characterized with fluorescent spectroscopes by monitoring the
emission peak at λ = 424 nm under excitation light of λ = 373 nm.
All data were expressed as mean SD and IC50 values were calculated by using
nonlinear regression analysis. The statistical significance was determined using a t test.
A p value less than 0.05 (i.e., p < 0.05) was considered to indicate statistical
significance for all comparisons.
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Abstract
Copper sulfide with near-infrared light absorption property is recently attracting
broad interest as a photothermal carrier for smart cancer therapy. Lipophilic copper
sulfide nanoparticle is preferred for high performance biomedical applications due to
the high affinity with tissues. But it requires complex multi-step synthetic process
under severe condition. Here, synthesis of hydrophobic copper sulfide possessing
surface plasmon resonance was retained by direct dry grinding of copper(II)
acetylacetonate with sulfur under ambient environment. The formed CuS
nanoparticles were in uniform size of ~10 nm, and they were monodispersed in pure
chloroform. Each covellite CuS nanocrystal surface was modified with oleylamine
through hydrogen bonding between sulfur atoms and amine groups of oleylamine.
While these oleylamine capped CuS nanoparticles showed uniform morphological
features, they demonstrated near-infrared light absorption for photothermal
applications. The facile and mild synthetic methodology described here opened a
powerful pathway for the design and preparation of photothermal lipophilic copper
sulfide nanomaterials for smart cancer therapy.
KEYWORDS:

Copper

sulfide;

oleylamine;

photothermal therapy.
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1. INTRODUCTION
Copper sulfide (CuS) nanocrystals with determined vacancies have recently
demonstrated to be capable of absorbing near-infrared (NIR) light irradiation (650–
900 nm) [1] and instantaneously converting into local heat. This unique property has
attracted broad interest for a variety of scientific and technological applications such
as solar cells, electroconducting electrodes, sensors, and clinics.[2–4] Notably, the
NIR light is able to penetrate through normal tissues with minimal thermal injury.[5]
The photothermal conversion effect of the CuS nanoparticles is independent of the
surrounding environment.[6,7] These features are especially useful for controlled drug
delivery and photothermal cancer therapy.[8–10]
For the synthesis of CuS nanoparticles with desired nanostructures, a series of
approaches have been developed, such as hydrothermal [11], solvothermal
method [12],

solid-state

reaction [13],

microemulsion[14],

and

reflux

condensation [15] have been developed. In order to endow the CuS nanoparticles with
NIR absorption, the as-prepared nanoparticles are usually further oxidized to produce
vacancies in the crystalline structures.[16] One of the most commonly used method is
based on the reaction of water soluble copper (II) salt and sodium sulfide as the
precursor at 90 °C through wet chemistry. The formed citric acid capped CuS
nanoparticles were applied as a photothermal coupling agent for PTA of cancer
cells in vitro and in vivo under the laser irradiation (808 nm, 16 W/cm2 and 24
W/cm2).[1] Alternatively, spherical copper (I) oxide nanoparticle aggregation was
used as an sacrificial template and it was hydrothermally treated in the presence of
polyvinylpyrrolidone (PVP) as a capping agent. Through Kirkendall effect, vacancies
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were introduced to CuS, forming hollow CuS nanospheres with surface plasmonic
performance.[6] In addition, the controllable hydrothermal approach was employed to
develop hydrophilic flower-like CuS superstructures with the assistance of PVP (K30,
0.2 g/mL) at 180 °C for 48 h. The resulting nanostructured CuS was used for ablation
of cancer cells upon 980 nm laser irradiation.[8] Unfortunately, these methodologies
generally involved complicated processes as well as excess toxic reagents, which
caused severe environmental pollution.
Recently, lipophilic nanomaterials have been developed for their drug delivery
into hydrophobic tissues such as brain and vascular tissues. To retain CuS
nanoparticles dispersible in organic phase, hot injection [17], cation exchange, [18]
and solventless approach[19] have been reported. Among them, hot injection method
based on high temperature reaction of copper (II) acetylacetonate and elemental sulfur
or sulfur provider (e.g., dodecanethiol) has been widely used. However, the lipophilic
CuS nanoparticles synthesized by these methods are not able to absorb NIR light.
Thus, they require additional complex oxidization treatment to show photothermal
performance.
In this paper, lipophilic CuS nanoparticles were synthesized by directly grinding
copper (II) acetylacetonate with sulfur in oleylamine at room temperature. Within a
few minutes of grinding in the ambient environment, the CuS nanoparticles were
attained in high yield. The resulting CuS nanoparticles were in uniform particle size of
~10 nm. Each nanoparticle had fine CuS nanocrystal core, which was capped with
oleylamine through hydrogen bonding between sulfur atom and amine group of
oleylamine. These nanoparticles were readily dispersible in chloroform without
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aggregation. While these CuS nanoparticle showed almost identical features as those
synthesized by the traditional solution based solvothermal approach, the current CuS
nanoparticles demonstrated distinguished absorption of NIR light, capable of
photothermal applications. Compared with the traditional solvothermal method, this
synthetic approach did not need excess toxic chemicals. And this process can scale up
easily. The unique facile synthetic method presented here sheds a considerable light on
the synthesis high performance lipophilic CuS nanoparticles for smart photothermal
therapy.

2. EXPERIMENTAL
Materials. Chloroform (>99%), cyclohexane (>99%) and ethanol (>99%) were
purchased from Fisher Scientific. Oleylamine, Sulfur, and copper(II) acetylacetonate
were bought from Sigma-Aldrich. All chemicals were used as received.
Synthesis of CuS Nanoparticles. To dry grinding synthesis of CuS
nanoparticles, 0.131 g of copper (II) acetylacetonate, 0.016 g sulfur and 2 mL
oleylamine were thoroughly mixed by grinding for 5 min using a mortar and a pestle.
During the grinding process, the mixture gradually became brown translucent liquid.
Then, the liquid was transferred into a round bottom flask and stirred at 70°C for 30
min, upon which the mixture color further turned from brown to green. Subsequently,
the resulting mixture was dispersed in 20 mL chloroform and centrifuge for 30 min at
11,000 rpm. The collected precipitation was dispersed in 10 mL chloroform, and 50
mL ethanol was added to precipitate the formed nanoparticles. These nanoparticles
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were collected by centrifugation and washed by excess ethanol repeatedly to remove
the remaining surfactant. After vacuum drying at room temperature, lipophilic CuS
nanoparticles were obtained.
As a comparison, CuS nanoparticle were prepared by traditional solution based
hot injection approach. 0.131 g copper (II) acetylacetonate was dissolved in a mixture
of 1 mL oleylamine and 3 mL chloroform, and 0.016 g sulfur was dissolved in 3 mL
oleylamine. The sulfur solution was dispersed in 10 mL cyclohexane and stirred at
70 °C for 10 min. After slowly injecting the copper (II) solution into the cyclohexane
solution and stirring at 1,000 rpm at 70 °C for 30 min, the mixture solution gradually
transformed from brown to green. The powder collected by centrifugation at 11,000
rpm for 30 min was then dispersed in 10 mL chloroform and mixed with 50 mL
ethanol to purify the resultant CuS nanoparticle. These purified nanoparticles were
further washed with ethanol for several cycles to exclude the excess surfactant and
dried in vacuum oven overnight.
Transmission

electron

microscope

(TEM). To prepare samples for

transmission electron microscope (TEM) observations, the corresponding materials
were suspended in chloroform and then dropped onto a carbon coated nickel micro
grid, followed by drying in air in fume hood. TEM observations were performed on a
JEOL 2100EX microscope operating at an accelerating voltage of 100 kV.
Fourier transform infrared (FT-IR) spectra were measured on a Nicolet
Nexus 670 spectrometer using KBr pellets.
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Powder X-ray diffraction (XRD) patterns of the synthesized nanoparticles
were recorded on Rigaku Ultima IV multipurpose X-ray diffractometer with a CuKa (λ
= 0.15405 nm) radiation source. The X-ray tube current was 100 mA with a tube
voltage of 40 kV. Each sample was scanned at a scan rate of 0.5° with resolution of
~0.02° from 2θ of 20° to 70°.
Dynamic light scattering (DLS). DLS analysis was proceeded with the
Malvern® nanoseries Nano-ZS90 nanoparticle size analyzer using a 1.0 cm path
length 4-way glass cuvette.
UV−Vis−NIR Spectroscopy.

Extinction spectra of all nanoparticles were

recorded with a PerkinElmer Lambda 1050 UV–visible–NIR spectrophotometer with a
quartz cuvette of 1.0 cm optical path length in the transmission mode employing pure
chloroform as the reference standard.
X-ray Photoelectron Spectroscopy (XPS). A Measurement was carried out on a
PHI 5500 system and Al Kα radiation. Multipak versions 6.1 as well as XPS Peak 4.0
software were utilized for analysis and curve fitting respectively. A combination of
Lorentzian and Gaussian functions was used for the least squares curve fitting.

3. RESULTS AND DISCUSSION
The TEM image of the CuS nanoparticles synthesized by the dry grinding
process is shown in Fig. 1a. Many nanoparticles were clearly observed. These metallic
nanoparticles were mainly in cubic geometry, and they were monodispersed. Some
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minor aggregation was caused by the evaporation of chloroform component during the
TEM sample preparation process, which was a common situation. Calculated based on
at least 300 particles, the average size for these CuS nanoparticles was ~10 nm. This
result matched well with the hydrodynamic particle diameter of the DLS analysis (Fig.
2), indicating excess surfactant was cleared and monodisperse fine nanoparticles
remained. As a comparison, CuS nanoparticles were prepared through the previously
reported solution based technique. As shown in TEM (Fig. 1b), the formed CuS
nanoparticle size was ~9 nm on average, and they were similar as the above
nanoparticles obtained by the dry grinding process. The solution based approach
derived nanoparticles were more spherical, because the liquid environment inhibited
directional crystal growth of the nanocrystals. Therefore, the dry grinding synthesis
approach achieved the fine nanocrystals, which was almost identical to the traditional
solution based method.
The XRD pattern of the powder sample prepared by the dry grinding method
presented clear peaks at 29.3°, 31.8°, 47.9 °, 52.7 °, and 59.3° (Fig. 3a), which were in
fair agreement with (102), (103), (110), (108), and (116) plane of covellite phase CuS
(powder diffraction file or PDF# 06-0464). The broad peaks inferred the nanoscale
nature of the sample.[20] The crystal size calculated based on (110) plane was ~ 7.73
nm. This size was relatively smaller than the particle size measured in TEM images
(10 nm), because a minor amorphous oleylamine layer was modified on the
nanocrystal surface. These characteristic peaks were identical to those prepared
through the solution based method. Therefore, the current CuS nanoparticles prepared
through dry grinding process formed high quality fine covellite CuS nanoparticles.
41

XPS spectra of the as-prepared CuS nanoparticles were summarized in Fig. 4.
The Cu 2p XPS spectrum exhibited 2p3/2 peak at 932.0 eV and 2p1/2 peak at 952.2 eV,
which were typical peaks for Cu(II) in copper sulfide.[21] The C 1s peak was resolved
as two peaks located at 284.6 eV and 285.7 eV, which respectively corresponded to
the hydrocarbon (C-C, C-H) in oleylamine and the C-N bond in oleylamine.[22] The S
2p peak of the CuS nanoparticles consisted of two distinct peaks. The one at 161.5 eV
originated from typical sulfide bond, and the doublets at 162 eV and 163.5 eV
demonstrated the formation of S–H bonds.[23] These peaks matched well with the
XPS spectra obtained from the CuS nanoparticle fabricated via the hot-injection
method (Fig. 5), supporting that the current CuS nanoparticles were capped with
oleylamine. Hydrophilic Sulfur atoms in CuS was qualified electron acceptors.[16]
Although it hardly interacted with the hydrophobic alkyl terminals of the oleylamine,
it readily accepted electron from the amine group in oleylamine, forming S–H bonds.
In the FTIR spectrum of the resultant CuS nanoparticles (Fig 6), the broad band
at ~3450 cm–1 was assigned to N-H stretching vibration of the amine group in
oleylamine,[24] the two bands at 2922 cm–1 and 2852 cm–1 were assigned to the
asymmetric (νas) and symmetric (νs) stretching vibrations of methylene (CH2=CH) in
the alkyl chain of oleylamine, the bands centered at 1634 cm–1 was attributed to N-H
bending vibration.[25-27] All of these characteristic bands were in fair agreement with
the FTIR spectrum of pure oleylamine. Hence, oleylamine was capping on the CuS
nanoparticles.
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Interestingly, the dry grinding synthesized CuS nanoparticles demonstrated broad
NIR absorption peaks centered at ~ 1100 nm (Fig. 7), which was very close to the
traditional CuS nanoparticles prepared by solution based technique. This strong
absorption suggested that the current CuS nanopaticles possessed localized surface
plasmon resonances for photothermal ablation applications.
Usually, it requires a liquid environment, high temperature, and N2 protection to
achieve fine CuS nanoparticles. The liquid environment allows oleylamine to form
micelles to direct the nucleation as well as growth of nanocrystals and prohibit
nanoparticle agglomeration. Meanwhile, high temperature accelerates the reaction and
inert environment prevents over oxidation of CuS to damage NIR absorbance (peak
absorbance < 1150 nm).[16] In the current study, it was proved that such conditions
were not mandatory for the synthesis of monodispersive fine CuS nanoparticles. The
grinding process realized fully contact of copper (II) salt with oleylamine for
complexation. The copper(II) salt complexed oleylamine consisted of hydrophilic salt
terminal and long alkyl chain groups, which still formed micelle structure and control
the crystal growth. Moreover, the existence of oxygen in the reaction process induced
the formation of vacancy in CuS crystals, resulting in NIR absorption. Although
further work is needed to clarify the actual reaction mechanism of the dry grinding
synthesis approach, this method attained monodisperse fine CuS nanoparticles with
surface plasmonic performance in a facile and mild process.
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Fig. 1. TEM micrograph for CuS nanoparticles synthesized by the dry grinding
approach (a) and the traditional hot-injection method (b). Bars: 20 nm.
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Fig. 2. Dynamic light scattering (DLS) analysis of the oleylamine coated CuS
nanoparticle deprived by the dry grinding approach (a) and the traditional hot-injection
method (b).

Fig. 3. XRD spectra of the CuS nanoparticles synthesized through the dry grinding
approach (a) and the traditional hot-injection method (b).
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Fig. 4. X-ray Photoelectron Spectroscopy (XPS) spectra of CuS synthesized by the dry
grinding approach. (a) C 1s, (b),Cu 2p, and (c) S 2p regions.
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Fig. 5. XPS spectra of CuS synthesized by the traditional hot-injection approach. (a) C
1s, (b) Cu 2p, and (c) S 2p regions.
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Fig. 6. FT-IR spectra of CuS synthesized by the dry grinding approach and the
traditional hot-injection method.

Fig. 7. Visible-NIR spectra of CuS nanoparticle (1 mM) dispersion in chloroform
synthesized by the dry grinding approach and the traditional hot-injection method.

4. CONCLUSIONS
Synthesis of monodisperse CuS nanocrystals was achieved by a facile one step
dry grinding process. The nanoparticles were composed of covellite phase CuS, and
the particle size was finely controlled as ~10 nm. The CuS nanoparticle surface was
capped with oleylamine by hydrogen bonding between sulfur atoms with amine group
of oleylamine. While the resultant CuS nanoparticles were highly comparable with
those prepared through traditional solvothermal method, the current approach was
carried out at ambient condition and decreased use of toxic solvents. This
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environmental benign opened a facile pathway for the large-scale production of
photothermal nanocrystals for applications smart drug delivery.

Acknowledgements
This work was supported by grants from the National Center for Research
Resources, the National Institutes of Health (RI-INBRE Award P20RR016457), and
the Rhode Island Foundation Medical Research Grant.

50

References
[2] Y. Cai J.C. Ho, S.K. Batabyal, W. Liu, Y. Sun, S.G. Mhaisalkar, L.H. Wong,
ACS Appl. Mater. Interfaces., 5 (2013), pp. 1533–1537.
[3] J.S. Chung, H.J. Sohn, J Power Sources, 108 (2002), pp. 226–231.
[4] L. Guo, D.D. Yan, D. Yang, Y. Li, X. Wang, O. Zalewski, B. Yan, and W. Lu. 8
(2014), ACS Nano, pp. 5670–5681.
[1] Y. Li, W. Lu, Q. Huang, M. Huang, C. Li, W. Chen, Nanomedicine, 5(2010), pp.
1161–1171.
[5] R.A. Weissleder, Nat. Biotechnol., 19 (2001), pp. 316–317.
[6] H. Zhu, J. Wang, D. Wu, Inorg. Chem., 48 (2009), pp. 7099–7104.
[7] G. Ku, M. Zhou, S. Song, Q. Huang, J. Hazle, C. Li, ACS Nano, 6 (2012) pp.
7489–7496.
[8] Q. Tian, M. Tang, Y. Sun, R. Zou, Z. Chen, M. Zhu, S. Yang, J. Wang, J. Hu,
Adv. Mater., 23 (2011), pp. 3542–3547.
[9] S. Song, C. Xiong, M. Zhou, W. Lu, Q. Huang, G. Ku, J. Zhao, L. G. Flores Jr.,
Y. Ni, C. Li, J. Nucl. Med., 52 (2011), pp. 792–799.
[10] M. Zhou, R. Zhang. M. Huang, W. Lu, S. Song, M.P. Melancon, M. Tian,
D. Liang, C. Li, J. Am. Chem. Soc., 132 (2010), pp. 15351–15358.
[11] Z. Cheng, S. Wang, D. Si, B. Geng. J. Alloys Compd., 492 (2010), pp. L44–L49.
51

[12] X.P. Shen, H. Zhao, H.Q. Shu, H. Zhou, A.H. Yuan, J. Phys. Chem. Solids, 70
(2009), pp. 422–427.
[13] S. Thongtem, C. Wichasilp, T. Thongtem, Mater. Lett., 63 (2009), pp. 2409–
2412.
[14] L. Chen, Y. Shang, H. Liu, Y. Hu. Mater. Des., 31 (2010), pp. 1661–1665.
[15] K. Mageshwari, S.S. Mali, T. Hemalatha, R. Sathyamoorthy, P.S. Patil, Prog.
Solid State Chem., 39 (2011), pp. 108–113.
[17] A. Ghezelbash, B.A. Korgel, Langmuir, 21 (2005), pp. 9451−9456.
[18] J.M. Luther, H. Zheng, H.B. Sadtler, A.P. Alivisatos, J. Am. Chem. Soc., 131
(2009), pp. 16851−16857.
[19] M.B. Sigman Jr., A. Ghezelbash, T. Hanrath, A.E. Saunders, F. Lee, B.A. Korgel,
J. Am. Chem. Soc., 125 (2003), pp. 16050−16057.
[16] P.L. Saldanha, R. Brescia, M. Prato, H. Li, M. Povia, L. Manna, V. Lesnyak.
Chem. Mater., 26 (2014), pp. 1442−1449.
[20] Y. Gu, J. Huang, Chem. Eur. J., 19 (2013), pp. 10971–10981.
[21] D. BRIGGS, M.P. SEAH, John WILLEY & SONS. 1 (1993), second edition.
[22] D.W.-P. Pang, F.-W. Yuan, Y.-C. Chang, G.-A. Li, H.-Y. Tuan, Nanoscale, 4
(2012), pp. 4562–4570.

52

[23] T. Sirtl, M. Lischka, J. Eichhorn, A. Rastgoo-Lahrood, T. Strunskus, W.M. Heckl,
M. Lackinger, J. Phys. Chem. C, 118 (2014), pp. 3590−3598.
[24] M. Nakaya, M. Kanehara, T. Teranishi, Langmuir 22 (2006), pp. 3485−3487.
[25] X.M. Lu, H.Y. Tuan, J.Y. Chen, Z.Y. Li, B.A. Korgel, Y.N. Xia, J. Am. Chem.
Soc., 129 (2007), pp. 1733−1742.
[26] W.B. Bu, Z.X. Chen, F. Chen, J.L. Shi, J. Phys. Chem. C, 113 (2009), pp. 12176–
12185.
[27] S. Mourdikoudis, L. M. Liz-Marzán. Chem. Mater., 25 (2013), pp. 1465–1476.

53

CHAPTER 3
This manuscript is being prepared for submission to Journal of American Chemical
Society.
Multifunctional Mesoporous Silica-Coated CuS Nanoparticles for Cancer
Therapy: Synthesis, Characterization and in vitro Evaluation
Yajuan Li,† Julie Scott,† Wei Lu†,*

†

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The

University of Rhode Island, Kingston, Rhode Island 02881, United States
*Corresponding author: Department of Biomedical and Pharmaceutical Sciences,
College of Pharmacy, The University of Rhode Island, 7 Greenhouse Road, Kingston,
Rhode Island 02881, USA. Phone: +1-401-874-5517. Fax: +1-401-874-5787. E-mail:
weilu@uri.edu

54

ABSTRACT: Chemo therapeutic drug-caused side effects are commonly seen in
clinical practice due to nonspecific toxicity and low therapeutic efficiency. Herein, we
reported a cancer chemo-photothermal multifunctional drug delivery system.
Polyethylene glycol decorated mesoporous silica nanoparticles entrapping CuS
nanoparticles (PEG-CuS@MSNs) were successfully synthesized and characterized for
the drug delivery application. Doxorubicin (DOX)-loaded PEG-CuS@MSNs showed
laser stimulated and pH-responsive properties. In vitro cell experiments demonstrated
that DOX-loaded PEG-CuS@MSNs combining laser exposure achieved the highest
rate of death of A549 cells, in comparison to that of PEG-CuS@MSNs-DOX alone.
These findings provided a promising drug delivery system for cancer combinatorial
therapy, which could significantly reduce drug dose and improve patient compliance.

KEYWORDS: magnetism, mesoporous silica nanoparticles, photothermal therapy,
doxorubicin
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INTRODUCTION
Cancer chemotherapy is often frightening because of not only the side effects but also
the high possibility of recurrence rate. In clinical practice, chemotherapy usually
accompanies with surgery, radiotherapy, etc. However, the 5-year relative survival
rate is still low, 68% for all cancers diagnosed between 2003 and 2009 in the United
States.[1] Various methods have been developed in addition to chemotherapy, such as
nano technique, targeted delivery, photothermal therapy, photodynamic therapy, etc.[2]
One highlighted trend is the application of nanotechnology, which delivers drug more
precisely at cancer cells and brings less damage to normal cells, thus diminishing side
effects. Beside, photothermal therapy can ablate cancer cells. Combination of chemo
and photothermal therapy with targeting feature into a nano delivery system would be
a practical and efficient solution worth trying.
Copper sulfide nanoparticles (CuS NPs) are a new class of photothermal sensitizer.
Their light absorption is not affected by the surrounding environment.[3, 4] They exhibit
stable light absorption towards near-infrared (NIR) light irradiation (650–900 nm),[5]
which will bring minimal thermal injury to normal tissues.[6] Immediately upon NIR
light absorption, CuS NPs generate heat and photothermally ablate tumor in vivo after
intratumor[7, 8] or intravenous injection.[9]
Although CuS NPs are promising, when applying to drug delivery, the
nanoparticle itself has limitation as a platform.[10] Since the surface is only one layer to
attach the chemicals, the loading efficiency is limited. To address this problem,
mesoporous silica is chosen considering its large pore size and high surface area.
Moreover, the technique of synthesizing a layer of mesoporous silica on the surface of
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inorganic template is relatively mature. There have been many reports on the
preparation of nanocrystals coated with mesoporous shells such as gold nanorods, [11]
iron oxide,[12] manganese oxide nanoparticle[13], graphene nanosheet,[14] etc. However,
studies on CuS NPs coated with mesoporous silica have not been reported.
In this study, a chemo photothermal drug system was formulated to increase drug
loading efficiency. Specifically, mesoporous silica spheres containing CuS NPs in the
core and DOX loaded in the silica channels (PEG-CuS@MSNs-DOX) were prepared.
Furthermore, these mesoporous silica spheres were applied to photothermal therapy. A
procedure for the synthesis of the CuS@MSNs-DOX is shown in Scheme 1.

Scheme 1. Schematic illustration of the synthesis process of PEG-CuS@MSNs-DOX.
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EXPERIMENTAL SECTION
2.1. Chemicals. Doxorubicin hydrochloride and Dulbecco's Modified Eagle
Medium (DMEM) were purchased from AK scientific and Lonza, respectively. All the
other chemicals were bought from Sigma-Aldrich without further purification. The
water was purified by using a Milli-Q Synthesis system (Millipore) with the resistivity
higher than 18.2 MΩ·cm.
CuS nanoparticle preparation. Copper acetylacetonate (0.131 g) and 0.032 g sulfur
(0.032 g, 1 mmol) and oleylamine (4.0 mL) were thoroughly ground and mixed for 5
min using a mortar and a pestle. During the grinding process, the mixture became a
brown, translucent liquid. Then, the liquid was transferred into a round bottom flask
and heated up to 70°C with magnetic stirring for 1 h. The color of the mixture then
turned from brown to green. The product was thereafter suspended in 20 mL
chloroform and transferred into a centrifuge tube and centrifuged for 30 min at 11,000
rpm. The supernatant was decanted and the precipitated pellet was collected. This
pellet was suspended with 10 mL of chloroform. Subsequently, 30 ml ethanol was
added to precipitate the nanoparticles. After centrifugation, the nanoparticles were
separated from the supernatant. Then wash the nanoparticles twice with ethanol to
remove the excess oleylamine. The final CuS NPs capped with surfactant were dried
at room temperature in a high vacuum. The as-prepared nanoparticles are
re-dispersible in chloroform.
Synthesis of CuS nanoparticles embedded in mesoporous silica spheres
(CuS@MSNs). 7.5 mg CuS nanoparticles in chloroform (0.2 mL) were added to a 1.5
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mL centrifuge tube, and total volume was complemented by chloroform to 0.5 mL.
The resulting CuS NPs suspension (0.5 mL) was added into 5 mL 0.02 g/mL
cethyltrimethylammonium bromide (CTAB) aqueous solution and stirred vigorously
for 30 min. The mixture gradually turned to turbid green color, indicating the
formation of an oil-in-water microemulsion. Then, the solution was heated up to 60 °C
for 10 min under stirring to evaporate the chloroform, resulting in a transparent green
CTAB stabilized CuS NPs suspension. The resultant suspension was added to a
mixture of 45 mL of water and 0.3 mL of 1 M NaOH solution and the mixture was
heated up to 70℃ under stirring. Then, 3 mL of ethylacetate and 0.15 mL of
tetraethylorthosilicate (TMOS) were added to the reaction solution in sequence. After
10 min, 50 µL of APTES was added and the solution was stirred for 1 h. The
precipitate was separated by centrifugation and washed with ethanol for 3 times and
suspended in 20 mL ethanol.
PEGylation of MSNs. 50 mg of methoxy poly (ethylene glycol) succinimidyl
glutarate (Mw 2000) dissolved in 20 ml ethanol was added to the as-synthesized
particles followed by stirring at 40°C for 3 h. The unreacted PEG was removed by
ethanol and water. The PEGylated particles were dispersed in phosphate buffer
solution (PBS, 10 mM, pH 7.4).
Loading of doxorubicin. The loading of doxorubicin for in vitro experiment were
performed as follows: PEGylated MSN solution (5 mL, 4 mg/mL) and doxorubicin
ethanol solution (5 mL of 2 mg/mL) were mixed by stirring at 300 rpm for 24 h. Then,
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the nanoparticles were isolated by centrifugation and vacuum dried overnight.
Fully-dried sample was suspended into 10 mL of 100 mM PBS buffer (pH 7.0).
Characterizations. To prepare samples for transmission electron microscope (TEM)
observations, the corresponding materials were ultrasonicated in pure water until
homogeneous suspension was formed, and the resulting suspension was then dropped
onto a nickel micro grid, followed by drying in air. TEM observations were
respectively performed on a JEOL 2100EX microscope operating at an accelerating
voltage of 100 kV. DLS analysis was proceeded with the Malvern® nanoseries
Nano-ZS90 nanoparticle size analyzer. UV–visible–NIR absorbance spectra were
obtained with a PerkinElmer Lambda 1050 UV–visible–NIR spectrophotometer with a
quartz cuvette of 1.0 cm optical path length in the transmission mode employing pure
water as the reference standard. FT-IR spectra were obtained with Thermos Scientific
Nicolet 380 FT-IR Spectrometer. X-ray diffraction (XRD) patterns of the produced
nanoparticles were recorded on a Rigaku Ultima IV multipurpose X-ray diffraction
system. Fluorescent spectra were measured by SpectraMax Multi-Mode Microplate
Readers.
In Vitro Release. In vitro release of DOX from the as-prepared nanoparticles by
adding 10 mg PEG-CuS@MSNs-DOX in phosphate-buffered saline (PBS, pH 7.4, 10
mM), and stirred constantly at 500 rpm. The NIR laser was administered as needed at
900 nm with power density of 2 W/cm2 for 2 min at time points of 1, 4, 8, 12 and 24 h.
The samples were collected before and after laser irradiation by centrifuge at 15,000
rpm for 10 min followed by filtration with 0.22 µm filter. The release medium was
replaced with a fresh one each time to maintain sink conditions. The amount of
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released DOX was monitored by fluorescent measurement. The fluorescent emission
peak at λ = 590 nm under excitation light (λ = 485 nm) of each solution was recorded
to determine the released DOX amount. As a comparison, in vitro release was
preceded identically without NIR irradiation. All measurements were performed in
triplicate.
Cell Culture. A549 cell line was cultured in DMEM media, supplemented with 10%
fetal bovine serum (FBS), L-glucose, glutamine, 100 U/mL penicillin and 100 µg/mL
streptomycin.
Cell uptake of PEG-CuS@MSNs-DOX. 8-well cover slide chambers were seeded
with A549 cells at 2 ×105 per well, and the cells were allowed to attach for 24 h. The
medium was replaced with 1 mL medium containing PEG-CuS@MSNs-DOX or Dox
solution (final DOX concentration 5 µM) and incubated for 4 h. The cells were
washed three times with PBS to remove the drug. Cell nuclei were stained with
Hoechst 33258. The cellular fluorescence were obtained as described in the preceding
paragraph.
Cytotoxicity. Cytotoxicity was measured by the 3-[4,5-dimethylthylthiazol-2-yl]-2,5
diphenyltetrazolium bromide (MTT) method. Briefly, A549 cells were seeded in
96-well plates at a density of 5 × 103 cells/well and incubated for 24 h prior to use.
The

cells

were

respectively

incubated

with

PEG-CuS@MSNs-DOX,

PEG-CuS@MSNs, and free DOX at equivalent drug concentrations ranging from 50
nM to 15000 nM for 4 h. Then the culture medium containing particles was replaced
with fresh medium and continued incubation for 20 h. Then, MTT tetrazolium salt
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(0.25 mg/ml) was added to each well and incubated in CO2 incubator at 37°C for 4 h.
Finally, 150 µL DMSO was added to each well dissolve formazan crystals and the
UV–vis absorbance peak at 570 nm was monitored by a plate reader.
In vitro efficiency test was carried out via trypan blue exclusive assay. A549 cells
were seeded in 12-well plates at a density of 5 × 104 cells/well and incubated for 24 h
prior to use. 20 µL of PBS control or 20 µL of 2 µg/mL (in Cu2+) nanoparticles
dispersed in PBS was added into designated wells of the 12 well plate. Then the plate
was incubated for 4 h. After irradiation with laser (900 nm, 2W/cm2) for 1 min, the
sample was stained by 0.4 mL trypan blue for 3 min. The stained sample was washed
twice with PBS, and mixed with 0.4 mL PBS. The in vitro efficiency was observed by
inverted microscope, and images were taken with a Cannon digital camera.
All data were expressed as mean SD. The statistical significance was determined
using a t test. A p value less than 0.05 (i.e., p < 0.05) was considered to indicate
statistical significance for all comparisons.
RESULTS AND DISCUSSION
Oleylamine coated CuS NPs was synthesized with a newly developed facile
non-solvent method. The TEM image suggested that CuS NPs were in flake shape
(Figure 1a) with an average size of 12 nm. The lateral view of some particles
demonstrates thin and rod-like structure, which agreed well with the CuS NPs
prepared by the complicated multi-step techniques.[15] It was considered that several
CuS nanoflakes stacked and were wrapped together into one silica nanoparticle during
the sol–gel reaction (Figure 1b). The average size of CuS@MSN was ~40 nm,
meeting the practical requirement for drug delivery.[16]. Figure 1c showed the
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PEG-CuS@MSNs nanoparticles (right) turned to purple after loading DOX (left). The
loading efficiency was as high as 18.4%.
DLS measurement presented a particle diameter of 58 nm. This was close to the
TEM result, but it was slightly larger (Figure 2). Because DLS measurement acquired
hydrodynamic data, and the swollen state of the nanoparticle inevitably became bigger
than the value at dry shrunk state.[17]
Zeta potential of CuS@MSN was –36.2 mV. Although the initial nanoparticle
surfaces are negatively charged, the coating of PEG on the surface brought the zeta
potential to nearly neutral, ~0.5 mV, which was preferable for drug delivery to the
negatively charged cell membranes.[18]
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Figure 1. TEM image of oleylamine-coated CuS NPs (a), and CuS@MSNs (b). The
red circle, a nanoparticle showing the panel of CuS NPs. The yellow circle, a
nanoparticle showing the lateral of CuS NPs stacks. A photograph (c) showed
PEG-CuS@MSNs-DOX (left) and PEG-CuS@MSNs (right).

Figure 2. Hydrodynamic particle diameter of CuS@MSNs by DLS analysis.
The XRD patterns of CuS@MSNs were exhibited in Figure 3. The typical peak of
SiO2 was found at 2θ = 21.7° (Figure 3). It also exhibits the CuS (Powder diffraction
file or PDF#65-3588) characters with 2θ at 29.3° (1 0 2), 31.8° (1 0 3), 32.9° (1 0 6),
48.0° (1 1 0), 52.7° (1 0 8), 59.3° (1 1 6), 69.4° (1 0 11).
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Figure 3. XRD pattern of CuS@MSNs.
The

UV-vis-NIR

spectra

of

CuS

NPs,

and

PEG-CuS@MSNs

and

PEG-CuS@MSNs-DOX all showed strong absorbance at the NIR region between 800
to 1400 nm, which is within photothermal treatment range (Figure 4). However, a
closer look at the spectra of the silica nanoparticles revealed that there was a slight
shift in the spectra, which might due to the change in the local refractive index of the
surrounding medium.[19] In addition, PEG-CuS@MSNs-DOX also exhibited the
typical absorbance band of Dox. It should be notified a red shift from 490 nm to 516
nm due to the influence of copper. (There is a detailed discussion on the interaction
between DOX and copper ion in Chapter 1.)
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Figure 4. UV-vis-NIR spectra of oleylamine coated CuS NPs (a), PEG-CuS@MSNs
(b) and PEG-CuS@MSNs-DOX (c). Concentration: 1.5 mM in copper.
The drug release behavior of PEG-CuS@MSNs-DOX was studied in the pH of 7.4,
6.0, and 5.0 buffer solutions over a 24-h period (Figure 5). It can be seen that DOX
release was pH dependent. At pH 5, the 24 h cumulative release of DOX for
PEG-CuS@MSNs-DOX was 17.9%. At pH 6.0, the released ratio decreased to 12.4%,
and dropped down to 5.7% when pH increased to 7.4. In addition, the release results
also indicated that NIR laser irradiation accelerated DOX release in various pH
conditions. Each time upon laser irradiation for 2 min at 2 W/cm2, released DOX is
enhanced 1-2 % immediately. The laser-triggered release was well responsive by
repeating the laser irradiation. The drug release slowed down when the laser was
switched off. Compared with PEG-HCuSNPs-DOX, the percentage release triggered
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by laser was much lower. Since DOX was loaded in the channels of MSNs, limited
proportion of the DOX were drove out of the channel by Cu NPs explosion upon laser
irradiation. But for PEG-HCuSNPs-DOX, laser irradiation brought devastating
damage to each nanoparticle, thus the DOX adsorbed or chelated to the surface was
released significantly. Back to the PEG-CuS@MSNs-DOX, in addition to pH
sensitive and laser triggered release, the release showed sustained release profile, as
over a period of 24 h, less than 20% of DOX was released. The triple-module release
profile, namely pH sensitive, laser controlled and sustained release, presented a
controlled release manner through which the drug could be specifically and extended
released at the tumor site either by applying NIR laser or replying on the acidic
environment of the tumor.
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Figure 5. Cumulative release profile of PEG-CuS@MSNs-DOX at different pH
buffers with 1 min of 2 W/cm2 NIR laser irradiation at 1 , 2, 4, 8, 12 and 24 h. Data
are expressed as mean ± SD (n = 3).
PEG-CuS@MSNs-DOX was internalized into A549 cells after 2 h incubation.
PEG-CuS@MSNs-DOX showed strong red fluorescence signal from DOX, despite
the quenching effect of DOX bond to PEG-CuS@MSNs. The fluorescence of DOX
was limited in spots scattered throughout the cytoplasm, indicating a distribution in
endolysosomal vehicles. (Figure 6) In comparison, free dox diffused in both cytoplasm
and nuclei after 2 h incubation.
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Figure 6. Fluorescence images of A549 cells after 2 hour incubation with DOX (a)
and PEG-CuS@MSNs-DOX (b), respectively. The cell nuclei were stained with
Hoechst 33258 (blue, the left column). Red, DOX, in the middle column. The overlay,
in the right column. Scale bar: 50 µm.
Cytotoxicity was tested by the methyl thiazolyl tetrazolium (MTT) assay in A549
cells derived from human lung carcinoma cell line (Figure 7). The results showed that
the cellular viability was estimated to be higher than 71% after 24 h incubation in the
presence of the PEG-CuS@MSNs or PEG-CuS@MSNs-DOX with Cu concentrations
of 0−10 µg/mL, indicating a relatively low cytotoxicity within this concentration range
(Figure 7). The IC50 of free DOX was about 0.12 µg/mL (data not shown) while the
IC50 of PEG-CuS@MSNs-DOX was significantly higher, 15 µg/mL, because of the
slow release profile of PEG-CuS@MSNs-DOX. PEG-CuS@MSNs-DOX exhibited
enhanced toxicity (IC50 = 59 µg/mL of Cu2+) than PEG-CuS@MSNs did (IC50 = 90
µg/mL of Cu2+).

70

Figure 7. Cell viability of A549 cells when incubated 4 h with (a) PEG-CuS@MSNs
or PEG-CuS@MSNs-DOX, with different dosages (n = 4).
The therapeutic efficacy test in vitro was explored on A549 cells incubated in
24-well plate. It was observed efficient photothermal ablation of the A549 cells only
after 1 min irradiation of the 900 nm laser in the presence of the nanoparticles. Also,
in the trypan blue assay as shown in Figure 7, few cells were dead either after laser
exposure alone (7b) or after treated with different nanoparticles without laser exposure
(Figure 7c and 7e). However, almost all the cells were dead after laser irradiation in all
nanoparticle groups (Figure 7d 7f and 7g). This was attributed to the efficient
intracellular uptake of PEG-CuS@MSNs-DOX after 2 h incubation.
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Figure 8. Optical images of A549 cells obtained after the cell viability (trypan blue)
test. (a) and (b), cells treated with PBS alone and PBS plus NIR laser (900 nm, 2
W/cm2, 1 min), respectively. (c) and (d), cells treated with PEG-CuS@MSNs alone
and PEG-CuS@MSNs plus NIR laser, respectively. (e) and (f), cells treated with
PEG-CuS@MSNs-DOX alone and PEG-CuS@MSNs-DOX plus NIR laser,
respectively. Scale Bar: 50 µm. (g) Quantification of cell viability of (a-f).
CONCLUSIONS
In summary, monodisperse CuS nanocrystals coated in uniform pore-sized
mesoporous silica nano spheres with an average particle size of 40 nm were
successfully synthesized. Mesoporous silica spheres adsorbed doxorubicin and
enabled high drug loading capacity. The release rate of doxorubicin was faithfully
controlled by pH, laser exposure and the surface property of mesoporous silica. They
showed photothermal effects on cancer cells upon laser exposure. These mesoporous
silica nanoparticles provide a facile pathway for versatile biomedical applications.
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Abstract:
Transdermal delivery offers an excellent route for drug and vaccine administration.
Nonetheless, it presents a critical challenge due to the skin’s lipid-rich outer stratum
corneum layer. Laser ablation perforates epidermis through selective photothermolysis,
making skin more permeable to hydrophilic and macromolecular drugs such as
peptides, proteins, and genes. This review summarizes recent applications to laser
ablation-enhanced transdermal delivery. Needle- and pain-free transcutaneous drug
delivery via laser ablation provides an alternative approach to achieve local or
systemic therapeutics.
Keywords: Laser ablation, Transdermal, Drug delivery, Microporation, Nanoparticle

77

1 Introduction
The development of transdermal drug delivery systems (TDDS) is attractive because
skin is the largest organ. TDDS have the distinct advantages over oral administration
or injections since they directly deliver drugs into the skin or even the systemic
circulation, avoiding first-pass clearance of liver thus enhancing bioavailability. TDDS
provide

sustained

and

steady-state

pharmacokinetics,

therefore

decreasing

administration frequency and improving the patient compliance. Further, TDDS avoid
the limitation of injections such as pain, accidental needle-sticks, and possible side
effects due to transiently high plasma drug concentration [1-3].
However, the skin presents a natural barrier to protect our body from the rough
environment. It forms multilayers in the epidermis, which include stratum corneum
(SC), stratum lucidum, stratum granulosum, stratum pinosum, stratum basale from
topical toward dermis. The SC is the outmost layer and consists of dead keratinocytes
or corneocytes intercalated with lipids [4]. This 10- to 20-µm thick layer is the
formidable barrier preventing most drug molecules from permeation. Only lipophilic
drug with molecular weight (MW) less than 500 Daltons is able to penetrate the skin
barrier, such as clonidine, fentanyl, and lidocaine [3, 5].
A variety of methods have been tried to enhance the permeability of the SC. Chemical
enhancers promote the drug penetration through the SC by disrupting the highly
ordered bilayer structures of the intracellular lipids in the SC [3]. Conventional
chemical enhancers such as Azone (1-dodecylazacycloheptan-2-one) as well as newly
developed biochemical enhancers like peptides are of interest [6, 7]. However,
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chemical enhancement has been shown little impact on delivery of hydrophilic drugs
and macromolecules and irritation to living cells in the deeper skin [3]. On the other
hand, physical enhancement techniques including mechanical and thermal approaches
have been used to make micrometer dimensions of disruptions to SC structures. These
micro-scale disruptions create channels of sufficient dimensions for passage of
macromolecules. The thermal ablation activated by microheaters,[8] radio-frequency
[9-11], superheated steam ejectate [12] or laser [13-16] is non-invasive technique to
selectively remove small portions of the SC. These perforations are temporary, since
the layers of the SC are continually replaced through the natural process of
desquamation [8]. Some of the physical enhancement technologies have been applied
in clinical trials for TDDS such as BA058 transdermal microneedle patch [17],
transdermal basal insulin patch with microporation [18], teriparatide acetate TDDS
transdermal [19], and electroacupuncture for opioid detoxification [20].
Laser ablation enhancement belongs to a physical approach that utilizes laser to
perforate or remove the SC barrier in order to enhance the drug penetration. Water and
pigments in the skin absorb the laser light energy and transform it into heat to achieve
theromolysis of the skin. The heating duration must be controlled within microseconds
in order to avoid heat propagation to deeper tissues [21]. The laser ablation approach
enables precise control of depth of skin permeation, having the potentials for
percutaneous delivery of biomacromolecules such as peptides, proteins, vaccines,
DNAs [15]. In this review, we will focus on recent progresses of laser ablation
enhanced TDDS.
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2 Direct laser ablation enhancement
Although many types of laser with a broad wavelength range (193 – 10,600 nm) are
available in clinical practice such as ruby laser, neodymium:yttrium-aluminum-garnet
(Nd:YAG) laser, alexandrite laser, CO2 laser and erbium:yttrium-aluminum-garnet
(Er:YAG) laser (Table 1), only a few are applied to transdermal delivery so far.
Pulsed CO2 and Er:YAG laser are in common use for SC ablation [22]. The ruby laser
(694 nm) and the alexandrite laser (755 nm) belong to near-infrared (NIR) laser (650 –
900 nm). The NIR light causes little tissue absorption or minimal thermal effect [23],
which is not sufficient to remove the SC. By contrast, the wavelengths of the CO2 and
Er:YAG laser are 10,600 nm and 2,940 nm, respectively. Both lasers directly induce
heating and microporation of the skin through water excitation and explosive
evaporation from the epidermis. Between these two laser types, the wavelength of the
mid-infrared Er:YAG light matches a principal absorption wavelength for water
molecules [13]. Compared with the CO2 laser, the Er:YAG laser is about 15 times
better absorbed in skin [22]. Therefore, the Er:YAG laser has a much higher ablation
efficacy and a lower ablation threshold [24]. The Er:YAG laser shows the reduced
thermal damage even in deeper crater holes in comparison with the pulsed CO2 laser
[22, 24]. These favorable properties make the Er:YAG laser an ideal light source not
only for skin surgery but also for enhanced transdermal drug delivery. A comparison
of three sources of laser, the ruby, CO2 and Er:YAG laser, on the skin permeability for
5-Fluorouracil (5-FU) showed that the ruby laser only moderately enhanced the drug
flux [25]. The Er:YAG laser with fluence at 0.8 – 1.4 J/cm2 enhanced the flux of 5-FU
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by 53 – 133 times than untreated skin. The CO2 laser increased penetration of 5-FU by
36 – 41 times under the fluences of 4.0 and 7.0 J/cm2 with certain thermal effects [25].
Laser-induced thermal ablation heats the skin to hundreds of degrees for very short
periods of time (micro- to milli-seconds) to disrupt the SC [3]. The extent of structure
alteration of the SC is proportional to the temperature locally elevated, i.e. (i)
disordering of SC lipid structure by temperature between 100oC and 150oC, (ii)
disruption of SC keratin network structure by temperature between 150oC and 250oC,
and (iii) decomposition and vaporization of keratin to create micron-scale holes in the
SC by temperature above 300oC [21]. Correspondingly, skin permeability was
increased from a few fold to three orders of magnitude [21]. For thermal
ablation-enhanced TDDS, high energy of laser with pulse duration less than
microseconds is required because it generates limited or negligible heat transfer to
surrounding tissue [13-16]. The microsecond-pulsed laser steepens the temperature
gradient across the SC. The skin surface is extremely hot but not the viable epidermis
and deeper skin tissues [12]. This technique referred to as “cold ablation”, thereby,
largely eliminates side effects and vastly improves safety.
In physically enhanced TDDS, the controllable depth and wound area of skin
perforation by the laser ablation should be well considered. Based on the clinical data
from microneedle and thermal ablation-enhanced transdermal delivery, micron-scale
defects in the SC are well tolerated by patients as long as no significant damage to
living cells in the viable epidermis and dermis [3]. To solve this issue, a laser
microporation technology called P.L.E.A.S.E.® (Precise Laser Epidermal System;
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Pantec Biosolutions) has been developed by using a diode-pumped fractional Er:YAG
laser (Fig. 1A) [14, 15]. Instead of conventional Er:YAG in clinics that ablates a
7-mm spot on the skin, P.L.E.A.S.E.® generates a matrix of identical micropores with
100 – 150 µm wide of each (Fig. 1B). Since the concentrated laser beam are divided
into microbeams, P.L.E.A.S.E.® efficiently and fractionally ablates skin with less
damages (Fig. 1C) [14]. In addition, the pulse duration of the fractional laser from
P.L.E.A.S.E.® is shorter than conventional Er:YAG laser to assure the localization of
heat transfer to the skin surface without allowing heat to propagate to the viable
tissues below. This technology is patient-friendly since it is programmed to precisely
control the number of micropores in unit area and depth of micropores based on the
laser fluence [15].
3 Photothermal nanoparticle-mediated laser ablation enhancement
The development of nanotechnology brings a breakthrough to the limited application
of NIR laser in TDDS. Gold nanostructures such as nanoshells [26], nanorods [27],
nanocages [28, 29], and hollow nanospheres [30] possess unique optical properties due
to strong and tunable surface plasmon resonance (SPR). They can be synthesized to
specifically absorb NIR light and convert photo energy into thermal energy to raise the
temperature of surrounding tissue [26, 31]. Nanoparticles with the property of
photothermal

coupling

effect

are

called

photothermal

nanoparticles.

Gold

photothermal nanoparticles can be applied to photothermal ablation therapy of tumor
cells [32-35], as well as the NIR laser-controlled drug release [36-40]. The absorbance
of NIR light is desirable because it causes minimal thermal injury to normal tissues
with optimal light penetration [23, 41]. Recently, a surfactant/protein/gold nanorod
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complex has been applied to transdermal delivery of proteins [42]. The solid-in-oil
dispersion system has been formulated through incorporation of gold nanorods as the
photothermal ablation enhancer to disrupt the skin barrier. This approach effectively
enhances the protein permeation through the skin in vitro and induces an immune
response in vivo [42]. In this application, instead of pulsed laser, a xenon lamp that
required high light power (6 W/cm2) and long duration of light exposure (20 min) has
been used to ablate the stratum corneum [42]. Therefore, the heat propagation to the
deeper tissue could be a major concern.
Semiconductor CuS nanoparticles (CuSNPs) are a new class of photothermal
nanoparticles that provide an alternative to gold analogs. Compared to gold, CuS is
much less expensive [43]. Irradiated with NIR laser, CuSNPs generate heat for
photothermal destruction of tumor cells [43-46]. Hollow CuSNPs (HCuSNPs) have
been utilized for photothermal ablation-enhanced transdermal drug delivery [47]. A
nanosecond-pulsed Nd:YAG laser in tandem with Ti:Sapphire laser (900 nm) has been
used to induce rapid heating of the nanoparticles and instantaneous heat conduction.
Such type of laser with nanosecond pulse duration provides focused thermal ablation
of the SC and minimizes skin heat accumulation. The average temperature of the
irradiated skin area only increases to ~40 – 50oC. The depth of skin perforation can be
precisely controlled by adjusting the laser power. The skin disruption by
HCuSNPs-mediated photothermal ablation significantly increases the permeability of
macromolecule drugs, providing effective percutaneous delivery [47].
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4 Drugs applied to laser ablation-enhanced transdermal delivery
In comparison with chemical enhancers that only improve the transdermal delivery of
small molecules, laser ablation enhancement makes micrometer dimensions of
disruptions to the SC structures suitable for the passage of both small and
macromolecules such as 5-FU [25, 48], lidocaine [14], diclofenac [16], human growth
hormone (hGH) [47], antithymocyte globulin (ATG) [15], ovalbumin (OVA) [42],
polypeptides [49], fluorescein isothiocyanate(FITC)-labled dextran (FD) [13],
nalbuphine [50], vitamin C [51], 5-aminolevulinic acid (ALA) [52], genes [53], and
stem cells [54] (Table 2).
Dextran, a hydrophilic macromolecular model drug, was used to evaluate the skin
permeation. By using a laser with fluence above 1.7 J/cm2, the transdermal transport
of FDs with molecular weight ranging from 4.4 kDa to 77 kDa was significantly
enhanced. The possible mechanism could be ablation of the SC layer,
photomechanical stress on intercellular regions, and alterations of the morphology and
arrangement of corneocytes by the Er:YAG laser. Further, the transdermal delivery of
hexameric insulin was higher than that of 38-kDa FD, suggesting the potential of laser
ablative transdermal delivery of Insulin [13].
ATG

and

Basiliximab,

two

marketed

antibodies

for

the

induction

of

immunosuppression, were studied with fractional Er: YAG laser [15]. The result
showed that the increase of pore numbers and laser fluence promoted the transdermal
permeation of the antibodies. Total delivery of ATG at 24 h after laser treatment (900
pores, at a fluence of 45.3 J/cm2) increased 82.8-fold over the control (untreated skin).
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Increasing laser fluence from 22.65 to 135.9 J/cm2 enhanced total ATG delivery from
1.70 ± 0.65 to 8.70 ± 1.55 µg/cm2, respectively. Similar penetration enhancement was
observed in Basiliximab. Moreover, the in vitro and in vivo result was well correlated
in a mouse model [15].
Topical delivery of DNA and RNA were also enhanced by laser ablation [53, 55].
With Er:YAG treatment, in vitro permeation of antisense oligonucleotides (ASOs)
increased

3 – 30-folds, depending on the laser fluence and the molecular weight of

ASO. In vivo results showed an enhanced expression of plasmid DNA in the epidermis
and subcutis [53]. Besides, it was also found that the delivery rate of siRNA was
raised by several times by the laser application [55].
Laser-enhanced

transcutaneous

protein

delivery

provided

a

non-invasive

immunization method [15, 56, 57]. The laser induced microporation allowed high
levels of antigen uptake. Further, transdermal delivery of vaccine targets the potent
epidermal Langerhans and dermal dendritic cells that generate a strong immune
response at much lower doses than hypodermic injection [58]. Transcutaneous
application of OVA via laser-generated micropores using the P.L.E.A.S.E® device
induced equal or higher immune responses compared to immunization by s.c. injection
[57]. In addition, targeting different layers of the skin had the potential to bias
different T cell polarization patterns [57]. The laser ablation enhancement followed by
transcutaneous immunization of lysozyme with 129 amino acids (14,307 Da) induced
antigen-specific IgG in the serum by 3-fold compared to the control without laser
treatment [56].
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In addition to deliver drug compounds, laser ablation-enhanced transdermal delivery
of adipose-derived stem cells (ADSC) were explored for wound healings [54]. After
fractional Er:YAG laser treatment, bromodeoxyuridine (BrdU)-labeled ADSC was
applied to the laser treated areas. After 4 and 48 hours, 12% and 5.5% of the stem cells
were found in the pretreated tissue, respectively [54]. This encouraging result
furthered the studies to optimize the technology for future clinical applications.
Because of high photothermal conversion effect, the gold nanoparticles were utilized
to achieve thermal ablation of skin to enhance transdermal delivery of OVA [42]. In
this study, a solid-in-oil dispersion was formulated to incorporate both the gold
nanorods and the drug. Therefore, the nanodispersion exerted two modules upon NIR
light irradiation, i.e. thermal ablation of the SC by the gold nanorods and enhancement
of skin permeation of OVA. In vivo experiment showed significant increase of
immune response for the gold nanorod-OVA solid-in-oil dispersion with NIR light
treatment than other groups [42]. Another study investigated the use of HCuSNPs as
photothermal ablation enhancers [47]. The permeability of human growth hormone
(hGH) in skin applied with HCuSNPs plus NIR laser was increased by 3 orders of
magnitude in comparison with that of the intact skin. In vivo study showed that
transdermal delivery of hGH using the HCuSNP-mediated photothermal ablation
technique reached an average bioavailability of 83% relative to that of the
subcutaneous injection. The peak drug concentration through transdermal delivery was
only one-third of that via subcutaneous delivery [47]. This was clinical beneficial
because it reduced the risk of side effect related to high concentrations and controlled
the drug concentration in a relatively stable level.
86

5 Conclusion
In conclusion, this review has discussed recent progresses of laser ablation technology
to enhance transdermal drug delivery. The success of delivery relies on locally thermal
ablation of the SC. By adjusting the laser fluence and exposure time, the depth of the
microporation can be controlled without harming the deeper living tissues such as the
dermis. The microchannels allow skin permeation of hydrophilic and macromolecular
compounds. Particular interest has been shown in the development of the
photothermal nanoparticles that mediate photothermal ablation of skin and deliver
drug in a single setting. As a clean, needle-free and non-invasive approach, laser
ablation enhancement technology shows great potential for future market.
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Table 1. Light sources for thermal ablation-enhanced transdermal drug delivery

Light Source

Wavelength

Pulse
Duration

Role of the light
in TDDS

Other Characteristics

Traditional Er:
YAG laser

2,940 nm

250 – 400
µs

Epidermal
ablation; Dermal
removal [25, 49]

One beam; Spot ablation

Fractional
Er:YAG laser

2,940 nm

10 – 300
µs

Fractional
Epidermal
removal [15]

Microbeams; Shorter
pulse; Less damage to
epidermis; Fractional
photothermolysis

Short pulse
CO2 laser

10,600 nm

50 ms

Epidermal
removal; Dermal
thermal injury
[25]

Ablation; Vaporization

Nd:YAG in
tandem with
Ti:sapphire
laser

690 – 950
nm

15 ns

Photothermal
ablation [47]

Surface plasmon
resonance by HCuSNPs

Xenon bulb

750 – 1,000
nm

Continuous
light

Photothermal
ablation [42]

Surface plasmon
resonance by gold
nanorods
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Table 2. Drugs/compounds used for transdermal delivery by laser ablation

Drug/Compound

Indication/Purpose

Molecule
Weight
(Da)

Enhanced
Fold of
Permeability

5-FU

Antitumor

130

133

Imiquimod

Immune response modifier

240.3

127

Lidocaine

local anesthetic

234.3

13

Diclofenac

Non-steroidal
anti-inflammatory drug
(NSAID)

296.15

118.9

Vitamin C

Model hydrophilic drug

176

260

Methotrexate
(MTX)

Psoriasis or rheumatoid
arthritis

hGH

Growth hormone deficiency

22 k

>1000

Antithymocyte/
Basiliximab

Immunosuppressive
antibodies

155 k/144
k

145/ N/A

OVA

Antigen

44 k

~8

Antigen

465 k

grass pollen
allergen

38 k

Beta-galactosidase
(bGal)
Recombinant Phl p
5
Equine heart
cytochrome c
Urinary follicle
stimulating
hormone
FITC-labeled
bovine serum
albumin
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Laser
source
Er:YAG
[25, 48]
Fractional
Er:YAG
[49]
Fractional
Er: YAG
[14]
Fractional
Er: YAG
[16]
Er:YAG
[51]
Er:YAG
[59]
Nd: YAG
tandem
with Ti:
sapphire
[47]
Fractional
Er: YAG
[15]
Xenon
light [42]

Significant
elevation

Fractional
Er:YAG
[57]

From 0 to >0

Fractional
Er:YAG
[60]

12.4 k
30 k

Model proteins

70 k

Peptides

Model peptides

716 –
2864

Dextran

Model hydrophilic

4.4 k

89

10 – 140
50

Er:YAG
[56]

Er:YAG

macromolecule
Insulin (hexameric)
Nalbuphine
Indomethacin

Diabetes mellitus
analgesic /Hydrophilic
model drug
NSAID/Lipophilic model
drug

10 – 150
k
36 k

From 0 to >0
>100

357

194

357

30

ALA

Anti-tumor/photosensitizer

131

260

Antisense
oligonucleotides

Test model

5k–8k

~29

Plasmid DNA

Express green fluorescent
protein

4.7 k base
pairs

160 base pair

RNA

Small interfering RNA

9266

10

Adipose-derived
stem cells

wound healing

--

5.5 – 12 % of
penetration

90

[13]

Er:YAG
[50]
Fractional
Er:YAG
[52]
Er:YAG
[53]

Er:YAG
[55]
Fractional
Er:YAG
[54]

Figures

Figure 1. P.L.E.A.S.E® technology. (A), The photograph of the hand-held device. (B),
Formation of a micropore array in the skin surface using the P.L.E.A.S.E® device. (C),
Hematoxylin and Eosin staining of micropores created in porcine ear skin after laser
microporation using the P.L.E.A.S.E® device at fluences of 4.53 J/cm2, 22.65 J/cm2
or 135.9 J/cm2 (from left to right). From reference.[15] Copyright Elsevier. Reprinted
with permission.
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Cancer is a disease when abnormal cells lose control in the body. It is caused by
genome damage or the disruption of cellular metabolic processes. It can be inherited
or induced by external factors. Cancer can form solid tumors on tissues or grow in the
blood. Solid tumors include cancers of the brain, lung, breast, colon and other tissues.
Current first-line treatments include surgery, chemo or radiation therapy. Surgery is
to remove a cancerous tumor. About 60% of cancer patients undergo surgery. The
limitation of surgery is that some cancerous cells may not been removed. So it is often
followed by a combination of other therapy to completely kill all cancer cells.
Chemotherapy is to use drugs to fight cancerous cells. However, the unselective
damage of normal cells will also cause significant side effects. Besides, the cancer
cells can develop drug resistance [1]. Radiation therapy is to use ionizing radiation,
(X-rays, gamma rays or electrons) to damage the DNA of cancerous cells. It is often
used to synergize chemotherapy or surgery. However, it can damage healthy tissues
close to the cancer cells or in the path of the radiation beam.
Photothermal therapy (PTT) is a therapeutic method in which electromagnetic
radiation is converted to heat to treat of various medical conditions including cancer.
The electromagnetic radiation resources include near infrared or visible light,
radiofrequency waves and microwaves. They can enhance the temperature in a
targeting region to destroy the cells[2].
PTT possesses a lot of advantages over other therapeutic methods in the treatment
of cancer. First, in comparison with the most common open surgery for tumor removal,
photothermal therapy only requires minimal invasion. It can accurately locate the
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tumor and reduce the harm to health tissue. Therefore, the average hospital stay time
can be significantly reduced. Second, when compared with commonly applied
chemotherapy, PTT largely reduces the side effects since it can be guided to focus on
and ablate the tumor, whereas chemo drugs do not differentiate the normal cells and
cancer cell. Third, PTT also shows advantages over radiotherapy, which has already
less the damage to healthy cells due to the precise delivery of high-energy radiation to
one particular location. Radiation nevertheless presents short-term risks such as skin
rash or problems with tissues or organs near radiation pass and long-term side effects
such as infertility or even secondary cancer due to radiation exposure.
The heat generated by laser has been used frequently in clinic practice. For example,
in dentistry, laser is used for photobiomodulation in treatment of recurrent aphthous
stomatitis and traumatic ulcers to accelerate healing process [3]. It is also used in
thermal therapy to heat malignant tissue and tumor. Other examples include laser
coagulation to seal blood vessels and stop bleeding, laser welding to join tissues and
blood vessels, laser shock waves to remove urinary, kidney and biliary stones [4].
The detailed strategy and outcome of PTT on tumor treatment is largely depending
on the properties of tumor, such as location, size, surface characteristic, water content,
etc. Generally, laser can only reach less than a few (3–4) centimeters under skin [5].
For superficial tumors, external heating could be achieved by superficial applicators.
For tumors deep inside the body but not close to a body cavity, a fiber need be inserted
into the center of the target tumor [6]. Moreover, it is important to keep well-localized
heating high enough in the tumor but not harm the surrounding normal tissue. To
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achieve this, additional use of real time imaging techniques such as MRI and
ultrasound imaging are required.
PTT has been applied to various solid tumors, including penile cancer, bladder
tumors, renal tumor, melanoma, cervical cancer, breast cancer and so on. For selected
cases of penile primary cancer in early stage, Nd:YAG or CO2 lasers therapy was
found effective [7,8]. For bladder and renal cancer, lasers is feasible for resection,
coagulation, and enucleation of non-muscle invasive bladder tumors, but it should
only be used in clinical trial setting or for patients who are not applicable to
conventional treatment either because of co-morbidities or other complications [9].
For cutaneous melanoma, multiple small (<1 cm) lesions respond well to the CO2 laser.
CO2 laser is recommended or palliative treatment of locoregional recurrence in a limb
[10]. Local laser ablation can also be used on precancerous dysplasia to prevent
cervical cancers [11].
There are also a lot of clinical trials for PTT on various carcinomas. For brain
tumors, patients with recurrence of glioblastoma who had previous received total
resection, chemotherapy and radiation therapy and ineligible for a secondary surgery
was proposed for MIR guided laser-induced thermal therapy (LITT) salvage therapy
[12]. Patients with resistant metastatic intracranial tumors who had previously
undergone chemotherapy, whole-brain radiation therapy, and radiosurgery were given
real-time magnetic resonance-guided laser-induced thermal therapy. The procedure
was safely carried out with minimal invasion in one day [13]. Other MRI-guided laser
interstitial thermal therapy was investigated on liver metastasis and prostate cancer
[14–16]. A minimal invasion method, percutaneous laser ablation, by inserting optical
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fibers into the cancer through 21-gauge needles, is safe and effective for cirrhotic
patients with hepatocellular carcinoma when resection or liver transplantation is not
possible [17]. In addition, tumor caused thrombus and mucostis are also eligible for
laser therapy [18,19].
Normally, tumor larger than 3 cm is not proper for laser ablation. However, a drug
might change this situation. Sorafenib, a multikinase inhibitor to reduce intratumoral
blood flow, might enhance the effectiveness of laser ablation on hepatocellular
carcinoma larger than 4 cm by decreasing cancer microvessel density and thus enlarge
laser-induced coagulation necrosis area [20].
Recently PTT has attracted new interest because of the arising of photothermal
nanoparticles, especially gold colloidal. Gold nanoparticles have superior light
absorption the excited electrons on the surface can produce strong localized heat thus
damage the cancer cell. Gold nanoparticles have involved in clinical trials. The first
example, which has phase II result, is gold nanoparticles with silica-iron oxide shell
for PTT treatment of atherosclerosis. The gold nanoparticles were integrated in stem
cells grown on a bioengineered patch. Then the patch was implanted onto the artery
through the minimally invasive cardiac surgery. Under near-infrared laser irradiation,
the nanoparticles in the patch can burn the plaque. The dense calcium area, fibrous and
fibro-fatty tissue with fulminant necrosis significantly decreased due to thermolysis of
the nanoparticles after 12 months [21]. In addition, Tumor necrosis factor (TNF) –
bound colloidal gold (Aurimmune®) was under phase I clinical trial. Patients with
advanced solid organ malignancies or primary and metastatic cancer undergoing
surgical resection received colloidal gold-bound TNF intravenously 12-78 hours prior
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to surgery. The antitumor effect and biodistribution is still under evaluation [22,23].
Another gold nanoparticle based laser photothermal therapy (Aurolase®) is also under
clinical trial for patients with refractory and/or recurrent tumors of the head and neck
and subjects with primary and/or metastatic lung tumors. The gold-silica (Auroshell®)
nanoparticles accumulated at the tumor respond to the interstitial illuminations of an
808-nm laser [24,25].
Besides gold nanoparticles, other types of nanoparticles are also widely explored.
For example, graphene, two-dimensional (2D) crystal of sp2-hybridized carbon atom
arranged in six-membered rings with high optical absorption in the NIR region are
utilized for PTT to ablating tumor [26,27]. Semiconductor nanocrystals such as CdS,
CdSe, CdTe, have been intensively used for fluorescence bioimaging due to the size
and shape-dependent quantum confinement effect [28]. They can efficiently emit
fluorescence when excited by visible or infrared light. Among those nanostructures,
some of them were highlighted as photothermal agents due to the high converting
efficiency of heat. Typical examples include nanostructures of MoS2, CuS, CuSe,
CuTe, etc [29,30]. Inorganic nanoparticles is hard to degrade in vivo and might
possess potential long- term toxicity. As a promising substitute, organic nanostructures
are explored for photothermal therapy based on the discovery of NIR-absorbing
organic nanomaterials. For instance, indocyanine green (ICG) has been approved by
FDA. Other NIR dyes include heptamethine indocyanine dye- IR780, IR783, IR808,
IR825, PcBu4, porphyrins [31–36]. In order to prepare more stable formulation with
various sophisticated purpose, the NIR dyes incorporated into micelles, liposomes or
even proteins, have been used for photothermal tumor ablation [37–39]. Conjugated
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polymers such as polyaniline, polypyrrole and PEDOT: PSS-PEG with extended
π-electrons also show high NIR absorbance as PTT agents, and have been found to be
robust photothermal agents [40–42]. In addition, metallic nanoparticles, mesoporous
silica nanoparticles and rare earth doped nanoparticles were also explored for
photothermal therapy of cancer [43,44]. It is not possible to highlight just one
nanoparticle since their parameters are so different. However, they should meet the
general requirement for in vivo application—deep tissue penetration ability for the
corresponding wavelength, significant photothermal conversion efficiency and decent
biocompatibility.
PTT is effective for recurrent tumors not sensitive to chemo drug or radiation.
However, PTT may not be effective against all — particularly cancers that have
already metastasized all over the body. Chemo drugs, in contrast, are able to distribute
throughout the body to destroy cancer cells that have spread, although chemo drugs
might cause huge side effects. The combination of PTT and chemotherapy might
conquer the limitation of PTT and chemotherapy. Doxorubicin (DOX) is a chemo drug
used for various cancers, such as blood cancers, many solid tumors and soft tissue
sarcomas. It works by intercalating DNA and increasing free radical. DOX has a
‘lifetime maximum dose’ due to its life-threatening dosage-dependent cardiac toxicity
[45]. In addition to DOX, other chemo drugs were tested for synergistic enhanced
phothermal therapy effect. For instance, small molecule chemo drugs like
camptothecin, a DNA enzyme topoisomerase I inhibitor, was loaded into hollow
copper sulfide nanoparticles for synergistic PTT therapy of cancer cells in vivo [46].
Hydrophobic curcumin (regulation multiple cell signaling pathways of tumor cells)
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was combined in Ag/Au nanogels for PTT [47]. Rotenone, a mitochondrial complex I
inhibitor, [48] and cisplatin (binding to and causing crosslinking of DNA) and so far
were also explored [49]. Besides, oligodeoxynucleotides containing cytosine-guanine
(CpG) motifs (a small single strand DNA functions as immunoadjuvant), single and
double strand DNA [50], tumor necrosis factor (TNF), antibody anti-VEGFR2, etc
were all investigated [51].
The CuS nanoparticles are considered as potent counterpart to gold nanoparticles,
since they are economically efficient, not affected by the surrounding (The PTT of
CuS nanoparticles originated from d-d* electron transition instead of surface plasmon
resonance effect), low long-term toxicity [52]. Various Cu2-xS nano composites (e.g.
chelator-free [(64)Cu]CuS nanoparticles, hollow nanoshell, core-shell nanoparticle
[46,53,54] have been extensively explored as a transformer of laser to thermal heat
either accountable for therapeutic effects or as vehicles for drug delivery.
Table 1 shows several representative examples of CuS nanoparticles in PTT therapy.
They are still undergoing bench-side research. However, they are very promising for
the clinical application. As shown in the table, some CuS structures are used for
synergistic chemo or immune therapy. Some of them possess very high (56.7%)
photothermal conversion efficiency. Most of them were tested in animal models with
subcutaneous inoculation of tumor cells. These mouse xenograft models are
convenient for intratumoral injection of nanoparticles and laser irradiation spot
location.
In my work, doxorubicin was selected as a model drug and hollow CuS
nanoparticle and oleylamine-coated CuS were selected as photothermal sensitizers.
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Doxorubicin utilized could easily form complex with copper through hydrogen bond
to load DOX. Due to the synergistic effect of photothermal therapy, only a small
amount of DOX is required, thus the risk of causing heart disease is expected to be
significantly decreased. The CuS nanoparticles synthesized exhibit remarkable
photothermal effect. Specifically, hollow CuS NPs have large surface volume and
considerable number of mesoporous pores beneficial for the drug loading. Unlike gold
nanostructures such as gold nanorods, they are photo-stable and more biocompatible.
Oleylamine stabilized CuS are readily dispersible in chloroform without aggregation
and have facile preparation method.
In conclusion, among various photothermal nanoparticles, CuS nanoparticles are
promising photothermal sensitizers in cancer PTT therapy low toxicity, low cost, high
efficiency. CuS nanoparticles have great potential for clinical application as gold
analogs.
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Table 1. Selective publications on in vivo CuS nanoparticles cancer photothermal
therapy

Nanoparticle
Structure
CuS

Drug
--

Cysteine-coated CuS
nanoparticles

--

Hydrophilic
flower-like
CuS
superstructures

--

Folate
receptor-targeted
CuS (FA-CuS) NP

--

Chelator-free
[64Cu]CuS
nanoparticles (NPs)

--

Hollow
nanoparticles

Camptothecin

CuS

Chitosan-coated
hollow
copper
sulfide nanoparticles
Cu9S5@mSiO2
core-Shell
nanocomposites

Oligodeoxynucle
otides containing
cytosine-guanine
Doxorubicin

Animal model
--

Administrati
on Route
--

Severe-combined
immunodeficient
mice (SCID) bearing
s.c. xenografts of
K7M2 osteosarcoma
cells
SCID bearing mice
s.c. xenografts of
PC-3 human prostate
cancer cells
Nude mice bearing
s.c.
folate
receptor-positive KB
cancer cells
Nude mice inoculated
s.c. with U87 human
primary
glioblastomacells
Kunming
mice
inoculated with H22
mouse hepatocellular
carcinoma cells on
the mammary fat
pads.
EMT6 murine mammary
carcinoma
-bearing mice
Nude mice of HCT
116 human colon
carcinoma model.
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Laser
Administrat
ion
λ = 808 nm
[55]

Intratumoral
injections

λ = 980 nm
0.72 W cm−2
10 min [56]

Intratumoral
injections

λ = 980 nm
0.51 W cm−2
5 min[57]

i.v. injection

λ = 808 nm
1.5 W cm−2
3 min [58]

Intratumoral
injections

λ = 808 nm
16 W cm−2
5 min [53]

i.v. injection

λ = 980 nm
0.7 W cm−2
5 min [46]

Intratumoral
injections
Intratumoral
injections

λ = 900 nm
2.0 W cm−2
40 s [59]
λ = 980 nm
0.72 W cm−2
10 min [60]

CuS
nanoparticles-decora
ted graphene oxide
functionalized with
polyethylene glycol
Cu7S4
Structure

Hollow

CuS NPs stabilized
with drug-conjugated
gelatin
CuS self-assembly
Shuttle-like bundles

Doxorubicin

Nude mice bearing
Hela cervical cancer
cells

Intratumoral
injections

λ = 980 nm
1 W cm−2
5 min [61]

--

SCID
mice
inoculated s.c. with
hepatocarcinoma cell
lines Hep3B cell

Intratumoral
injections

λ = 980 nm
0.72 W cm−2
10 min [62]

Doxrubicin

--

--

λ = 808 nm
6 W cm−2
10 min [63]

--

--

--

[64]

SCID bearing s.c.
xenografts of K7M2
osteosarcoma cells

Intratumoral
injections

--

--

--

--

Nude mice bearing
Hela cervical cancer
cells

Intratumoral
injections

Cu7.2S4 nanocrystals
Gadolinium chelate
functionalized CuS
NPs
Fe3O4@Cu2−xS
Core−Shell
Nanoparticles

λ = 980 nm
0.72 W cm−2
7 min [65]
λ = 808 nm
－
6 W cm 2)
5 min [66]
λ = 980 nm
0.6 W cm−2
10 min [55]
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